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Resumo 
A transtirretina (TTR) é uma das várias proteínas conhecidas por sofrerem alterações 
conformacionais e formarem  agregados e fibras amiloides insolúveis e altamente estáveis que se 
acumulam nos tecidos extracelulares causando doenças. A amiloidose senil sistémica, a 
polineuropatia amiloidótica familiar, a cardiomiopatia amiloidótica familiar e a rara amiloidose 
seletiva do sistema nervoso central são as principais patologias em que a TTR está implicada.  
Embora o transplante de fígado e o medicamento Tafamidis sejam usados como abordagens 
terapêuticas, atualmente não há cura ou tratamento totalmente eficaz para as amiloidoses da TTR 
e várias estratégias terapêuticas têm vindo a ser desenvolvidas visando as diferentes etapas do 
processo de formação de fibras. A desagregação de oligómeros e fibras amiloides é uma dessas 
estratégias. Para selecionar eficientemente compostos com esse efeito é necessário desenvolver 
um protocolo específico de screening que consiga identificar e caracterizar a interação desses 
compostos com as fibras.  
Com este objetivo três protocolos diferentes de formação de fibras de TTR tipo selvagem 
foram estudadas para selecionar e caracterizar o protocolo de formação de fibras mais relevante 
e apropriado. Adicionalmente a técnica STD NMR (diferença de transferência de saturação por 
ressonância magnética nuclear) foi selecionada e usada para estudar a interação da doxiciclina, 
composto conhecido por desagregar fibras amiloides de TTR mutante, com fibras de TTR tipo 
selvagem, e um ensaio de dispersão dinâmica de luz foi desenvolvido e utilizado para caraterizar 
o efeito deste composto na desagregação de fibras.  
Os resultados demonstraram que o protocolo de formação de fibras induzidas pelo calor 
possui algumas vantagens sobre os outros protocolos mas requer uma melhor caracterização. A 
STD NMR foi aplicada com sucesso na caracterização da interação da doxiciclina com as fibras 
de TTR tipo selvagem, indicando os resultados que a doxiciclina interage de modo diverso com 
amiloide de TTR tipo selvagem formado em diferentes condições experimentais. O ensaio de 
dispersão dinâmica de luz permitiu a caracterização do efeito da doxiciclina nas fibras ao longo 
do tempo e demonstrou que a doxiciclina desagrega fibras amiloides pré-formadas de TTR tipo 
selvagem.  
 
Palavras-chave: Amiloide, transtirretina, doxiciclina, desagregação de fibras 
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Abstract 
Transthyretin (TTR) is one of several proteins that are known to undergo conformational 
changes and form aggregates and insoluble highly stable amyloid fibrils, which accumulate in 
extracellular tissues, causing diseases. Senile systemic amyloidosis (SSA), familial amyloid 
polyneuropathy (FAP), familial amyloid cardiomyopathy (FAC), and the rare central nervous 
system selective amyloidosis (CNSA) are the main pathologies in which TTR is implicated.  
Although liver transplant and more recently the medicine Tafamidis are in use as therapeutic 
approaches, currently there is no cure or completely effective treatment for TTR amyloidosis and 
several therapeutic strategies targeting different steps of the fibril formation pathway are under 
development. The disruption of amyloid aggregates and fibrils is one of those strategies. To 
properly select compounds for that purpose a specific screening protocol that can identify and 
characterize the interaction of the compounds with the fibrils must be developed.  
With this purpose three wild type‑TTR (WT‑TTR) fibril formation protocols were studied 
to select and characterize the most relevant and appropriate fibril formation protocol. 
Additionally saturation transfer difference nuclear magnetic resonance (STD NMR) was selected 
and used to study the interaction of doxycycline, a known TTR fibril disrupter, with WT‑TTR 
fibrils, and a dynamic light scattering (DLS) assay was developed and performed to characterize 
the effect of this compound on fibril disruption.  
The results show that the heat-induced fibril formation protocol have some advantages over 
the other fibril formation protocols but requires further characterization. 1H STD NMR was 
successfully applied in probing the interaction of doxycycline with WT‑TTR fibrils, with the 
results indicating that doxycycline interacts diversely with WT-TTR amyloid fibrils formed in 
different experimental conditions. The DLS assay allowed the characterization of the effect of 
doxycycline on WT‑TTR fibrils over time and demonstrated that doxycycline disassembles 
pre‑formed WT‑TTR fibrils.  
 
Keywords: Amyloid, transthyretin, doxycycline, fibril disruption  
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Chapter 1: Introduction 
1.1-Amyloid 
 
1.1.1 - The multiplicity of protein states 
 
From a chemical point of view proteins are the most structurally complex and functionally 
sophisticated group of biomacromolecules. They participate in the majority of biological processes 
partaking in a great diversity of vital functions. Following their synthesis, in order to perform their 
biological function, the majority of the proteins need to acquire a specific three-dimensional structure, 
the native structure, in a process called folding. In addition to the native structure proteins can also 
populate various other states (Figure 1) including disorder and partially ordered conformations and 
different aggregated assemblies.  
The populations of the different states and their interconversion are determined by different factors 
such as their different thermodynamic stabilities, free energy barriers associated with the corresponding 
transitions and also the rates of synthesis and degradation, the propensity to interact with chaperones 
and to undergo post-translational and other chemical modifications1.  
Despite the quality control mechanisms present in the cell, such as chaperones and the proteasome2, 
proteins are sometimes irreversibly  trapped as misfolded conformations. Misfolded proteins cannot 
correctly accomplish their biological activity. Additionally they often aggregate and/or interact 
inappropriately with other cellular components leading to impairment of cell viability and eventually to 
cell death3. Many diseases known as misfolding or conformational diseases result from their presence in 
a living system.  
Currently considerable attention is given to a group of protein folding diseases known as amyloidosis. 
In these diseases specific peptides or proteins fail to fold or to remain correctly folded and then 
aggregate (often with other components) so as to give rise to “amyloid” deposits in tissues and organs. 
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Figure 1: Possible protein conformational states and assemblies1. Schematic representation of some of the states 
accessible to a polypeptide chain following its synthesis in a ribosome. The amyloid state of a protein is a highly ordered form 
of aggregate in which the polypeptide chains adopt a fibrillar structure.  
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1.1.2 - The amyloid state of proteins and disease  
 
1.1.2.1- Proper t i e s  o f  Amylo id 
 
Amyloid structures have a series of specific tinctorial and biophysical characteristics, namely a very 
high level of kinetic and thermodynamic stability, that reflect a common core structure based on the 
presence of highly organised β-sheets. According to the modern biophysical definition amyloid is an 
unbranched protein fiber whose repeating substructure consists of β-strands that run perpendicular to 
the fiber axis, forming a cross-β sheet of indefinite length4.  
Amyloid fibrils from different proteins are very similar at the nanometre length scale5,6. Electron 
microscopy and atomic force microscopy (AFM) studies showed that they appear as unbranched 
filamentous structures only a few nanometres in diameter (6-12 nm) but often micrometres in length1,7. 
It was also observed that they consist of multiple protofilaments that twist around each other to form 
mature fibrils8.  
X-ray diffraction studies identified X-ray fiber diffraction patterns with a meridional reflection at 4.7 
Å corresponding to the inter-β strand spacing and an equatorial reflection at 6–11 Å corresponding to 
the distance between stacked β-sheets5 (Figure 2). 
 
 
 
 
 
 
 
 
Figure 2: Structure of Amyloids. (A) Amyloid fibrils are composed of long filaments that are visible in negatively stained 
transmission electron micrographs. (B Schematic diagram of the cross-β sheet structure in a fibril, with the backbone 
hydrogen bonds represented by dashed lines, indicating the repetitive spacings that give rise to (C) the typical fibre diffraction 
pattern with a meridional reflection at 4.7 Å (black dashed box) and an equatorial reflection at 6–11 Å (white dashed box)4.  
 
Recent developments in cryo-electron microscopy, solid-state NMR spectroscopy and X-ray diffraction 
studies of peptide microcrystals confirmed previous observations and allowed to obtain amyloid 
structures at atomic resolution9,10.  
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The internal order of amyloid structures gives them specific tinctorial properties. These properties are 
very important in the clinic as well as in the laboratory. Congo red is typically used in histological 
staining of amyloid, where it shows a typical red-green birefringence under polarized light when bound 
to amyloid11. Thioflavin T is used in pre-clinical research as in vitro staining and detection method, it 
exhibits a fluorescence spectral red-shift when bound to amyloid12. 
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1.2.2- Amyloidos i s  
 
Many human diseases are associated with protein aggregation. To date there are approximately 50 
disorders which are associated with the formation of extracellular amyloid fibrils or intracellular 
inclusions with amyloid-like characteristics6. These disorders can be broadly grouped into three 
categories: neurodegenerative conditions, in which aggregation occurs in the brain; non-neuropathic 
localized amyloidosis, in which aggregation occurs in a single type of tissue other than the brain; and 
non-neuropathic systemic amyloidosis, in which aggregation occurs in multiple tissues6. In table 1 some 
examples of diseases belonging to each category can be observed. 
 
Table 1: Examples of human diseases associated with amyloid. 
 
 
In several forms of amyloidosis the bulk of the deposited protein is enough to disrupt normal organ 
or tissue function. However in some cases precursors to amyloid fibrils, such as low molecular weight 
oligomers and/or structured protofibrils, rather than the mature fibrils into which they convert are the 
likely origins of pathological behaviour13,14. 
Disease Aggregating protein or peptide 
Neurodegenera t iv e  d i s eases   
Alzheimer’s disease 
Spongiform encephalopathies 
Parkinson’s disease 
Amyotrophic lateral sclerosis 
Huntington’s disease 
Familial amyloidotic polyneuropathy 
Amyloid-  β peptide 
Prion protein or its fragments 
α-synuclein 
Superoxide dismutase 1 
Huntingtin fragments 
Transthyretin mutants 
Non-neuropath i c  lo ca l ized  amylo idos i s   
Amyloid light chain amyloidosis 
Amyloid A amyloidosis 
Senile systemic amyloidosis 
Haemodialysis-related amyloidosis 
Lysozyme amyloidosis 
Immunoglobulin light chains or its fragments 
Serum amyloid A1 protein fragments 
Wild-type transthyretin 
β2-microglobulin 
Lysozyme mutants 
Non-neuropath i c  sy s t emic  amylo idos i s   
Apolipoprotein A1 amyloidosis 
Type II diabetes 
Injection-localized amyloidosis 
Apo A-1 fragments 
Amylin 
Insulin 
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1.2 - Transthyretin  
 
The protein currently known as transthyretin (TTR) was first discovered in 1942 in human plasma 
and in the cerebrospinal fluid (CSF)15,16 receiving the name prealbumin because of its electrophoretic 
migration pattern compared to albumin. Afterwards, to better describe its main physiological roles that 
are the transport of thyroid hormones17 and retinol trough binding to retinol binding protein18, the name 
was changed to transthyretin. TTR belongs to the group of amyloidogenic proteins being involved in 
several amyloidosis. 
 
1.2.1- Genetic aspects 
The human TTR gene is found on chromosome 18q11.2-q12.119. To date over 100 mutations have 
been identified20. The vast majority is disease causing and related to amyloid deposition affecting 
predominantly peripheral nerve and/or the heart21. Only a small portion of TTR mutations is seemingly 
non-amyloidogenic21.  
 
1.2.2- Structure 
Human TTR is a homotetrameric protein with a total molecular mass of 55 kDa. Each monomeric 
subunit has 127 aminoacids and consists of eight β-strands and a short α-helix (Figure 3A). Each 
monomer has a β-sandwich fold composed of two four-stranded β-sheets labelled DAGH and CBEF 
(Figure 3B). The dimer is formed mainly through antiparallel β-strand interactions between the H-
strands, resulting in a continuous eight stranded β-sheet comprising strands DAGH and H’G’A’D’. The 
F strands also participate in the dimerization through interactions between side chains and 
interconnecting water molecules (Figure 3C)22. 
To form the functional and soluble tetramer, two dimers interact through hydrophobic contacts and 
hydrogen bounds between the AB and GH loops as well as strand H (Figure 3D)23. 
 
1.2.3- Synthesis and catabolism 
In humans transthyretin is mostly biosynthesized in the liver24 but also in the choroid plexuses of the 
brain25, retinal pigment epithelial cells of the eye26 and α-cells of pancreatic islets27. It is predominantly 
found in the plasma (0.2 mg/ml=3.63 µM in the tetrameric form) and represents a high proportion of 
the total protein in the cerebrospinal fluid28.  
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TTR has a biological half-life of approximately 2.5 days and it is catabolized primarily by the liver and 
by excretory loss via the kidneys and gastrointestinal tract29.  
A 
Figure 3: Primary, secondary and three-
dimensional structure of human transthyretin. 
(A) Primary and secondary structure representation 
of the TTR monomer (PDB code 1F41); (B) 
Monomeric unit structure (PDB code 1F41); (C) The 
monomer arrangement of the dimer (PDB code 
1F41); (D) Tetrameric, three-dimensional structure 
with each monomer represented in a different colour 
(PDB code 1DVQ). Images B, C and D were 
produced with the Swiss-Pdb Viewer. 
B C 
D 
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1.2.4- Function 
 
TTR transports the thyroid hormones T4 (3,5,3’,5’-tetraiodo-L-thyronine or thyroxine) and T3 
(3,5,3’-triiodo-L-thyronine) (Figure 4) having two sites for hormone binding (Figure 5). TTR binds 
approximately 15-20% of the circulating thyroid hormones, thyroxine binding globulin has the highest 
affinity for this hormones and binds approximately 75% while albumin, having the lowest affinity, binds 
5%30. In the central nervous system TTR is the only identified thyroid hormone carrier. 
 
 
 
 
 
 
Figure 4: Chemical structure of 3,5,3’-triiodo-L-thyronine (T3) and 3,5,3’,5’-tetraiodo-L-thyronine or thyroxine (T4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Three-dimensional structure of transthyretin in complex with two molecules of T4 (represented in grey)31.  
 
Retinol (Figure 6) is secreted from the liver bound to the retinol binding protein (RBP). RBP binds to 
TTR preventing extensive loss of the low molecular weight RBP through glomerular filtration18. Both 
the apo and holo form of RBP has the ability to bind to TTR, but affinity is significantly higher for the 
holo form32. The RBP-TTR complex (Figure 7) transports 90-95% of retinol. 
T3 T4 
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Figure 6: Chemical structure of retinol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Three-dimensional structure of transthyretin in complex with RBP (represented in green) and retinol 
(represented in grey)33. 
 
Besides this well studied carrier functions, it has been suggested over the years that TTR may also 
participate in the maintenance and function of the central nervous system. TTR has been shown to play 
an important role in behaviour, cognition, amidated neuropeptide processing and nerve regeneration34. It 
has also been suggested that TTR has a neuroprotective action in Alzheimer’s disease and cerebral 
ischemia34. 
Recently it has also been found that TTR can function as a protease and seems able to proteolytically 
process apolipoprotein AI, cleaving it at residue Phe225 positioned in the C-terminus35.  
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1.2.5 - Transthyretin amyloidosis 
 
Fibrillar structures formed by TTR are implicated in several amyloidosis (Table 2). TTR amyloidosis 
can be divided in two types: age-related or senile amyloidosis and familial or hereditary amyloidosis 
(Table 2). In the age-related amyloidosis fibrils are derived from wild-type TTR (WT-TTR) and in 
hereditary amyloidosis TTR variants are implicated. 
 
1.2.5.1- Age-re lated/seni l e  amylo idos is  
Senile Systemic Amyloidosis (SSA) is strongly correlated with ageing, typically presenting itself after 
age 60 and affecting 25% of the population over the age of 8036. SSA is an idiopathic disease 
characterized by the deposition of WT-TTR fibrils37 in many organs. It is often asymptomatic however 
in some individuals, predominantly men, it can give rise to heavy deposit formation in the heart resulting 
in congestive heart failure38. 
 
1.2.5.2- Famil ia l/heredi tary amylo idos is  
Familial Amyloid Polyneuropathy (FAP), Familial Amyloid Cardiomyopathy (FAC) and the rare 
Central Nervous System selective Amyloidosis (CNSA) are pathologies caused by the more than 100 
different TTR variants known39.  
Familial Amyloid Polyneuropathy 
FAP was first discovered and described by the portuguese physician Prof. Corino de Andrade as a 
peculiar form of peripheral neuropathy40. After been reported in Portugal in 1952 was subsequently 
described in Japan41 and Sweden42 and it is now believed to occur worldwide. TTR was identified in the 
amyloid deposits in 197843. 
In this autosomal dominant disorder mutant forms of TTR aggregate to form amyloid fibrils that 
deposit in tissues, especially the peripheral nervous system. The most common mutation is by far the 
Val30Met44, typically found in Portugal, Sweden and Japan but also worldwide39. 
The clinical onset of this lethal pathology is characterized by sensory peripheral neuropathy of the 
lower limbs, primarily affecting pain and temperature sensation. These symptoms are later followed by 
motor impairments and autonomic dysfunction with the cardiocirculatory, gastrointestinal and genito-
urinary systems affected45.  
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The disease onset, typically in the third or fourth decade of life, and disease progression depend on 
the existing mutation. However multigenic and environmental modulating factors may contribute to the 
course of the disease46.  
Familial Amyloid Cardiomyopathy 
In FAC TTR amyloid can infiltrate any or all of the cardiovascular structures, including the 
conduction system, the atrial and ventricular myocardium, valvular tissue, and the coronary and large 
arteries47 which may lead to restrictive cardiomyopathy and heart failure. The most common TTR 
mutation associated with FAC is the Val122Ile and is found in 3-4% of the African-American 
population in the USA48. 
Central Nervous System selective Amyloidosis 
CNSA or oculoleptomeningeal amyloidosis (OA) is a more uncommon disease where the site of 
amyloid deposition is the central nervous system (CNS), predominantly leptomeninges and subarachnoid 
vessels49. Approximately 13 different mutations, such as Asp18Gly and Ala25Thr, have been associated 
with the development of CNSA in humans49. These mutations are generally the most destabilizing and 
amyloidogenic. 
 
Table 2: Human Transthyretin-Associated Amyloidosis50 
Amyloidosis Clinical classification Amyloid constituting Affected population 
Senile Systemic 
Amyloidosis 
Cardiomyopathy WT-TTR 25% over 80 years of 
age worldwide 
Familial Amyloid 
Cardiomyopathy 
Cardiomyopathy Mutant TTR (e.g. Val122Ile) 3-4% of the African 
American population in the 
USA 
Familial Amyloid 
Polyneuropathy 
Peripheral neuropathy +/-
cardiomyopathy 
Val30Met European (Portugal, 
Sweden) and Japanese 
Mutant TTR  Worldwide 
Central Nervous 
System Selective 
Amyloidosis 
CNS amyloidosis Highly destabilized mutants of TTR 
(e.g. Ala25Thr, Asp18Gly) 
Rare 
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1.2.6 - Transthyretin amyloid formation 
 
Over the years the molecular mechanisms and kinetics involved in amyloid formation have been 
subject of considerable scientific interest51. As previously described, amyloid TTR is involved in several 
diseases. Understanding the molecular mechanism of aggregation is very useful to prevent or control 
amyloid formation and has already contributed to the design of small molecules that can inhibit certain 
steps of the aggregation process52.  
The aggregation process starts with the dissociation of the native tetramer into monomers followed 
by partial unfolding of the monomeric units that become prone to aggregation53–55(Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: TTR amyloid cascade56. 
 
Until recently the details of TTR fibril formation from the monomeric amyloidogenic intermediate to 
mature fibrils were not well understood and the characteristics of the intermediate assembly states 
remained elusive. AFM and dynamic light scattering were used to describe the morphological features of 
transthyretin protofibrillar amyloid intermediates57. In this study annular oligomers composed by 8–16 
monomers were the first morphologically distinct intermediates observed in acid-induced WT-TTR 
aggregation.  
A novel kinetic model was presented this year to describe the aggregation of WT-TTR triggered by 
the addition of salt to acid-unfolded TTR monomers58. This model proposes a two-step kinetic 
mechanism to analyse the aggregation reaction kinetics. According to this model the initial step is faster 
and leads to the formation of globular oligomers with 6 to 10 monomers, the second step is slower 
leading to the formation of fibrils. 
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1.2.7 - Transthyretin Amyloid structure and toxicity 
 
As previously described amyloid fibrils have common structural morphologies being composed of 
multiple protofilaments that twist around each other to form mature fibrils. Early studies of Val30Met 
TTR amyloid fibrils using image reconstruction from electron micrographs showed that the diameter of 
the fibrils was about 130 Å and in cross-section they exhibited 4-fold symmetry with four proto-
filaments, each measuring 40 to 50 Å across, arranged around a central hollow core59. Subsequently the 
structure of these fibrils was investigated by fibre diffraction methods using synchrotron radiation and it 
was discovered a novel molecular structure consisting of β-­‐‑sheets extended in regular helical twists along 
the length of the fibre. This 115.5 Å repeat along the fibre axis was interpreted as a 24  β - stranded unit, 
with its constituent β strands arranged perpendicular to the fibre axis, forming a complete helical turn 
around an axis parallel to the fibre axis60. 
Posterior X-ray diffraction studies hypothesized that axially arrayed TTR monomers constitute the 
protofilament61, this was corroborated by the size of the repeating pattern, 29 Å which is similar to the 
size of the monomer61.  
Efforts have been made to determine the three-dimensional arrangement of the TTR subunits in the 
amyloid fibrils using site-directed spin labelling EPR studies62 and H/D exchange NMR63. In agreement 
with the previous experimental data a structural model of an amyloid protofilament was constructed 
using molecular modelling methods64. This model is formed by two extended continuous β-sheets with 
the β-strands perpendicular to the main axis of the protofilament and a helical twist with a period of 48 
β-strands (Figure 9).  More recently amyloid fibbers of WT-TTR were studied using protease digestion, 
mass spectrometry and solid-state NMR65. This study proposed a different structure and arrangement of 
the monomeric subunits with a particularly different configuration of the β-sheets (Figure 10).  
 
Figure 9: (A) Schematic representation of the TTR protofilament model obtained, showing the size of half of the 
repeating unit. (B) Protofilament cross-section dimension including only the core β -strands64. 
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Studying the TTR amyloid structure and the arrangement of the subunits is of particular importance 
in the development of therapies that may prevent the association of the amyloidogenic species or induce 
disaggregation of the amyloid fibrils.  
 Regarding TTR amyloid toxicity it has been demonstrated that amyloid fibrils are not the most toxic 
species in the aggregation pathway. In vitro studies on human neuroblastoma cell lines have shown that 
monomeric and small oligomeric species are very cytotoxic and mature TTR fibrils do not induce 
considerable toxicity14,66,67. Furthermore Sousa and colleagues verified that small nonfibrillar deposits of 
TTR are linked with nerve degeneration in FAP patients and demonstrated the cytotoxicity of the 
prefibrillar structures in cell culture assays68. 
Ultrastructural analysis of amyloid-laden cardiomyocytes from autopsied patients with FAP revealed 
intracellular structural changes that correlated with the degree of amyloid deposition. This cells were 
physically limited by amyloid fibrils with loss of cross-talk with surrounding cells and tissues69. It was 
hypothesized that this may lead to metabolic disturbances, cell degeneration, and ultimately cell loss69. 
The other histopathologic and cell culture studies presented in this work showed that TTR amyloid 
fibrils and prefibrillar aggregates had no acute cytotoxic effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Plausible models for the TTR amyloid65. (A) Representation of the previously suggested TTR amyloid model 
with strands B, E, and F (front) comprising one sheet and strands A, G, and H (back) comprising the other sheet of the 
amyloid core62. The C and D strands have been excluded for clarity. (B) New TTR amyloid model based on protease 
digestion and solid-state NMR spectroscopy results. The N-terminal region up to residue 50 was excluded for clarity. The D 
strand and part of the D loop interact with the E strand, while the former F strand and helix becomes the linker to the sheet 
composed of the interacting G and H strands. Isoleucine residues (red) and phenylalanine residues (green) are labeled65.  
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1.2.8 - Therapeutic Strategies for Transthyretin Amyloidosis 
 
To date there is no cure or completely effective treatment for TTR amyloidosis. Considering the 
current knowledge about TTR and TTR amyloid formation, various strategies targeting different steps of 
the pathway are under development (Figure 11)70,71.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: TTR amyloid formation and therapies71 
 
1 .2.8.1 -  Strategy  1:  Inhibi t ion o f  TTR synthes i s  
Currently the most successful treatment for hereditary systemic TTR amyloidosis is orthotopic liver 
transplantation (OLT). The rationale behind the method is that since TTR is produced mainly by the 
liver, the synthesis of mutant TTR is abolished. 
 Regarding the treatment of FAP, OLP has reportedly halted the progression of clinical 
manifestations72. The first OLT for a FAP patient was performed in 1990 and currently approximately 
120 OLTs are performed worldwide each year73. OLT reportedly prolonged the survival of FAP 
Val30Met patients but was less effective with non-Val30Met FAP patients who have cardiomyopathy or 
leptomeningeal dominant symptoms74. OLT is also a very invasive procedure, with high healthcare costs 
and limited to the availability of healthy livers.  
Gene therapy for TTR amyloidosis is currently under development. Small interfering RNAs (siRNAs) 
and antisense oligonucleotides (ASO) are effective gene-silencing tools and have been effective in 
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inhibiting the production of various TTR mutants and WT-TTR both in vitro and in vivo75,76. A phase 3 
clinical trial using an ASO and a phase 2 clinical trial using a siRNA targeting TTR are ongoing77.  
The occurrence of ocular complications in FAP patients increases with time78 even after OLP because 
retinal pigment epithelial cells of the eye continued to synthesize mutant TTR. Retinal laser 
photocoagulation may be used to mitigate ocular manifestations in FAP patients. This technique, 
commonly used to treat many retinal diseases, damages the retinal pigment epithelium and has already 
prevented progression of amyloid deposition in the vitreous and on the retinal surface in certain FAP 
patients without causing any adverse effects79. 
 
1 .2.8.2 -  Strategy  2:  Prevent  the Formation o f  the  Amyloidogenic  Intermediate  
TTR tetramer dissociation leads to formation of amyloidogenic intermediate species. Therefore, 
stabilizing tetrameric TTR is a promising method to prevent amyloid formation. Presently two drugs 
with this mechanism of action, tafamidis and diflunisal are in development.   
Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, has been approved in Europe 
(2011) and Japan (2013) for treatment of adult FAP patients with early symptomatic polyneuropathy to 
delay neurological impairment. In the clinical trials this small molecule has delayed peripheral neurologic 
impairment in 60% of the patients in early stages of the disease80,81.  
Diflunisal, a nonsteroidal anti-inflammatory drug developed in 1971, is also in clinical trials for its 
repurposing as a FAP medication. It has already demonstrated the reduction of rate progression of 
neurological impairment and preservation of quality of life82. 
Long-term therapeutic effects of those TTR stabilizers are not yet known, they are far of being 
regarded as a curative treatment. Currently a great number of structurally diverse small molecules are 
being investigated to act as tetramer stabilizers. One of the major difficulties in the selection of these 
compounds is the non-specific binding to other plasma proteins compromising their efficacy.   
 
1.2.8.3 -  Strategy  3/4: Prevent  the  Assoc iat ion o f  the  Amylo idogenic  Spec i es  and 
Disaggregat ion o f  the  Amylo id Fibr i l s  
Blocking the association of the amyloidogenic units into aggregates and fibrils may be regarded as a 
promising therapeutic strategy. This approach has some drawbacks because the structure of this 
intermediary amyloidogenic unit is not yet completely known may be highly heterogeneous. Fibril 
disruption is also a possible therapeutic strategy that has been under study in the last years.  
Immunotherapies are one of the candidates for TTR amyloidosis treatment using these strategies. 
Several antigenic mapping methods have been used to study whether major antigenic sites differed for 
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WT-TTR, mutant TTR and in situ amyloid fibrils83. A TTR mutant, Y78F, designed to destabilize the 
native structure has been shown to expose a cryptic epitope recognized by a monoclonal antibody that 
reacts only with highly amyloidogenic mutants presenting the amyloid fold or with amyloid fibrils84. 
Immunization of transgenic mice carrying the most common FAP-associated TTR mutant (Val30Met) 
with TTR Y78F showed a significant reduction in TTR deposition suggesting that Y78F induced 
production of an antibody that reacts specifically with deposits and leads to an immune response 
effective in removing/preventing TTR deposition85.  
Epigallocatechin-3-gallate (EGCG), 4′-iodo-4′-deoxydoxorubicin (IDOX), tauroursodeoxycholic acid 
(TUDCA) and doxycycline are regarded as possible therapeutic compounds. EGCG, a natural 
polyphenol from green tea, was demonstrated to act as a tetramer stabilizer of TTR Val30Met86 and also 
as an amyloid fibril disruptor in vitro87. In vivo studies with FAP mice models confirmed this results88. A 
single-center observational trial showed that patients suffering from cardiomyopathy derived from 
mutant TTR, treated with green tea or green tea extracts presented improvements in their condition, 
namely a decrease of cardiac wall thickness and mass, suggesting that EGCG halted TTR deposition and 
increase TTR amyloid deposits clearance89.   
IDOX, a tetracycline antibiotic, was shown to interact with five types of amyloid fibrils, including 
TTR amyloid, inhibiting fibril growth90.  In vitro studies with Leu55Pro-TTR and IDOX demonstrated 
that this compound disrupts preformed amyloid fibrils without producing toxic species91.  
TUDCA, a natural compound with potent anti-apoptotic and anti-oxidant actions that reduces 
cytotoxicity in several neurodegenerative diseases92, was tested in transgenic mice for human Val30Met-
TTR mutation leading to a decrease in TTR deposition93. The mechanism for this result remains to be 
elucidated, however, the effect as a TTR stabilizer and inhibitor of fibril formation was discarded93. 
Doxycycline (Figure 12) is a synthetic tetracycline derivative with similar antimicrobial activity. 
Doxycycline has demonstrated anti-amyloidogenic activity in vitro94, acts as Leu55Pro-TTR amyloid  fibril 
disrupter in vitro91 and disaggregates amyloid deposits in Val30Met TTR transgenic mice with 
concomitant decrease of various tissue markers95,96.  
This compound also has been administrated in combination with TUDCA in the TTR Val30Met 
transgenic mouse model97. This approach resulted in a significant reduction in TTR deposition and 
associated tissue markers. Currently a phase-II clinical trial using this combination is in progression 
displaying promising results98. In this clinical study no severe adverse effects were reported, no clinical 
progression of cardiac involvement was observed and the neuropathy remained substantially stable over 
one year98. 
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Figure 12: Structure of doxycycline.  
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Aims 
The overall objective of this work is the development of an experimental protocol to screen for WT-
TTR fibril disrupters.  
More specifically the aims are: 
ü Select and characterize the most relevant and appropriate fibril formation protocol; 
ü Choose appropriate experimental methods that can provide relevant information about the 
effect of the candidate compounds on fibril interaction and/or disruption; 
ü Define the most effective order of assays to be performed that can save time and resources 
without compromising the screening process; 
ü Validate the protocol using compounds that already have been established as TTR fibril 
disrupters, for example doxycycline.  
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Chapter 2: Experimental section 
2.1 – Materials 
 
Recombinant human WT-TTR was produced in an Escherichia coli expression system and purified 
according to a previously described protocol58.  
Doxycycline was purchased from AK Scientific (Union City, USA). Hydrochloric acid was obtained 
from Merck (Frankfurt, Germany).  
Sodium azide, thioflavin-T, deuterium oxide, dimethyl sulfoxide-d6  and all the other reagents used for 
buffer and sample preparation were purchased from Sigma-Aldrich (St. Louis, USA), and obtained with 
the highest purity available.  
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2.2 – Methods  
2.2.1 - Dynamic Light Scattering 
 
Dynamic Light Scattering (DLS), also known as Photon Correlation Spectroscopy or Quasi-Elastic 
Light Scattering, is a well-established technique for measuring the size and size distribution of molecules 
and particles in solution typically in the submicron region99. This technique can be used to measure 
samples consisting of particles suspended in a liquid (e.g. proteins, polymers, micelles, nanoparticles, 
colloidal dispersions and emulsions). This method has several key advantages: it is non-invasive and non-
destructive, allowing complete sample recovery, small quantity of sample is required and allows fast 
analysis and high throughput 99.  
 
2.2.1.1 -  Princ ip les  
DLS measures Brownian motion relating this to the size of the particles. Colloidal sized particles in a 
liquid undergo random motion due to multiple collisions with the thermally driven molecules of the 
liquid (Brownian motion). The larger the particle, the slower the Brownian motion will be.  
When a solution with particles in Brownian motion is irradiated with a monochromatic light beam, 
typically a laser light, the intensity of the scattered light fluctuates over very short timescales at a rate that 
is dependent upon the size of the particles. Analysis of these intensity fluctuations yields the Brownian 
motion velocity. The Brownian motion velocity is determined by a property called translational diffusion 
coefficient (D).  
For a solution of given viscosity, at constant temperature, the rate of diffusion or diffusion coefficient 
is inversely related to the particle size according to the Stokes-Einstein equation (Equation 1):  𝑑 𝐻 = !!!!"#    (Equation 1) 
Where d(H) is the hydrodynamic diameter, D is the translational diffusion coefficient, κ is the 
Boltzmann’s constant, T is the absolute temperature and η is the viscosity of the solvent. 
The diameter measured in DLS is called hydrodynamic diameter referring to how a particle diffuses 
within a fluid, it is the diameter of a sphere that has the same translational diffusion coefficient as the 
particle. This value will depend not only on the size of the particle “core”, but also on any surface 
structure, as well as the concentration and type of ions in the medium.   
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2.2.1.2 -  Instrumentat ion 
The DLS set up for the Beckman Coulter N5 Submicron Particle Size Analyser, used in this work, is 
illustrated in figure 13. In a DLS experiment the laser passes through the focusing lens and then hits the 
optical cell with the solution containing the particles being analysed. The light is scattered and the six 
fiber-optic receptors, stepper motor and photomultiplier (PMT) tube define the angle of scattered light 
detection. The PMT produces a current pulse for every photon of scattered light detected, transforming 
a variation of intensity in a variation of voltage. This burst of current passes to the pulse amplifier and 
discriminator (PAD) and the PAD determines whether the pulse is larger than a certain threshold level 
in which case it is shaped and amplified so that it is easily detected by the digital autocorrelator100.   
The digital autocorrelator computes the autocorrelation function (ACF) of the current pulses. The 
ACF is the mathematical transformation of the signal into a function (Equation 2): 
 𝐺 𝜏 =< 𝐼 𝑡 ×𝐼(𝑡 + 𝜏) >    (Equation 2) 
 
Where: G(τ) = ACF; I(t) = intensity detected at time t; I(t+τ) = intensity detected at time t+τ; τ = 
delay time; <> = quantity enclosed is a time average. By computing the ACF for a large range of τs, a 
quantitative measure of the light fluctuations (or the changes in the pattern of particles) is found. This 
quantitative measure of the time scale of fluctuations (called the decay time) is directly related to particle 
size100.  
The microprocessor receives the information of the digital autocorrelator and takes the commands 
trough the software translating them into the appropriate form to drive the digital autocorrelator, set the 
temperature or select an angle for measurement100.  
 
 
 
 
 
 
 
  
Figure 13: Functional block diagram of the Beckman Coulter N5 Submicron Particle Size Analyser100. 
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2.2.1.2 – Resul t  analys i s   
The Beckman Coulter N5 Submicron Particle Size Analyser controlled by the PCS software can 
provide two forms of data analysis: unimodal and size distribution processor (SDP). Both analyses can 
provide results in terms of particle size and/or molecular weight.  
Unimodal analysis is a faster method, but it only determines the mean-scattering-intensity-weighted 
particle size (particle mean size) with the standard deviation of the size distribution and the 
polydispersity index (PI) of the particle size distribution. The limitation of the unimodal analysis is that it 
is less accurate for complex distributions. Although unimodal results are more accurate for size 
distributions that are not extremely polydisperse, the mean size provided is still a reliable measure of the 
sample's mean size even if the true distribution is complex. PI values below 0.1 indicate that the sample 
is monomodal (narrow distribution), values over 0.3 indicate that the sample is considered polydisperse.  
SDP analysis determines the particle size distribution without assuming a unimodal distribution. Since 
the N5 equipment does not count individual particles the different decay times (due to the different 
sized particles) are mixed together in a composite ACF that characterizes all the particles simultaneously. 
The software mathematically separates the decay times using an algorithm based on a FORTRAN 
program called CONTIN. SDP analyses provide histograms of particle size distributions that can be 
displayed in three different formats: intensity, volume (weight) or number. In intensity histograms the 
magnitude of each peak is proportional to the percent (% amt) of the total scattered intensity due to 
particles of each size.  The intensity distribution can be converted to a volume distribution if the 
complex refractive index of the particles is known. Number distributions are determined by dividing the 
volume results by the cubed diameter of the particles in the distribution. 
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2.2.2 - Saturation Transfer Difference Nuclear Magnetic Resonance 
 
Saturation transfer difference nuclear magnetic resonance (STD NMR) is one of the ligand-based 
nuclear magnetic resonance techniques most widely used for the study of protein-ligand interactions101. 
Nowadays this technique is an important tool in drug discovery. STD NMR can be used as a screening 
technique for the identification of lead compounds and in the identification of ligand moieties important 
for binding102.  
STD NMR has several key advantages in comparison with other NMR based screening methods such 
as reduced protein (or receptor) requirements, no in depth NMR information about the target is needed 
because the focus is on the ligand signals, it is applicable to large molecular weight proteins and it is 
relatively easy to applicate103.  
However, this technique also suffers from some drawbacks. This method can only be used to probe 
low affinity interactions (dissociation constant, KD, ranging from 10
-8 M to 10-3 M)104 , it does not detect 
high-affinity ligands that undergo slow chemical exchange on the NMR time scale or ligands with very 
low affinity.  
The acronym STD describes the bases of the method that involves saturation and difference. 
Basically an STD experiment involves subtracting a spectrum in which the protein was selectively 
saturated (on-resonance spectrum) from one recorded without protein saturation (off-resonance 
spectrum) (Figure 14). The on-resonance spectrum is obtained by irradiation on the protein signals at a 
frequency range where no ligand protons resonate. Selective saturation of a single protein resonance will 
result in a rapid spread of the magnetization over the entire protein (spin diffusion)105. If the ligand binds 
to the receptor protein the saturation also transfers to the ligand105. The off-resonance spectrum is taken 
without protein irradiation. In the difference spectrum only the signals of the ligand that received 
saturation transfer from the protein via spin diffusion, through the nuclear Overhauser effect (NOE), 
will remain. 
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Figure 14: Scheme of the STD NMR experiment103. 
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2.2.3 - Circular Dichroism  
 
Circular dichroism (CD) is defined as the unequal absorption of left-handed and right handed 
circularly polarized light (Equation 3) occurring when a molecule contains one or more chiral 
chromophores. CD spectroscopy measures the CD of molecules over a range of wavelengths.   
 ∆𝐴 𝜆 = 𝐴 𝜆 !"#! − 𝐴 𝜆 !"#$    (Equation 3) 
 
A chiral chromophore is optically active yielding a CD signal for one of the following reasons: (a) it is 
intrinsically chiral because of its structure, (b) it is covalently linked to a chiral centre in the molecule or 
(c) it is placed in an asymmetric environment by virtue of the three-dimensional structure adopted by the 
molecule106. 
CD is an important technique in the study of large biological molecules namely proteins and 
especially for secondary structure determination107. In proteins, the chromophores of interest include the 
peptide bond (absorption below 240 nm), aromatic amino acid side chains (absorption in the range 260 
to 320 nm) and disulphide bonds (weak broad absorption bands centred around 260 nm)106.  
Far-UV CD encompasses the spectral region between 180 and 250 nm and provides information 
about protein secondary structure. Absorption in this region is predominantly based on the excitation of 
electronic transitions in amide groups, there is a weak but broad nèπ* transition centred around 220 
nm and a more intense πèπ* transition around 190 nm. 
The peptide backbone forms characteristic secondary structures such as α-helices, β-sheets, turns, and 
disordered sections with specific Φ, Ψ dihedral angles and H-bond patterns affecting the CD spectrum. 
These different structural elements have characteristic CD spectra (Figure 15). 
CD data is usually presented in terms of ellipticity (θ) (degrees) or differential absorbance (ΔA).  
Differential absorbance can be converted in ellipticity using the following expression (Equation 4): 𝜃obs   =   32.98  ∆A    (Equation 4)  
 
For protein far-UV CD this units are usually converted in mean residue ellipticity using the following 
expression (Equation 5): 
 θ MRW =    !!"#×!""×!!!×!×!"      (Equation 5) 
 
Where:  [θ]MRW =  mean residue ellipticity (deg.cm2.dmol-1); 𝜃𝑜𝑏𝑠 = observed ellipticity (degrees); MM= 
molecular mass (Da); c = concentration (g/ml); l = pathlength (cm); nA = number of aminoacids 
residues per protein or peptide.  
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Figure 15: Circular dichroism spectra of polypeptides and proteins with representative secondary structures107. 
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2.2.4 - Fluorescence Spectroscopy 
 
Fluorescence spectroscopy, also known as fluorometry or spectrofluorometry, is a type of electronic 
spectroscopy. This technique involves using a beam of light (usually UV) to excite the electrons in 
certain chemical groups, named fluorophores, causing them to emit light of a lower energy, tipically but 
not necessarily visible light.   
As represented in the Jablonski diagram (Figure 16) when the fluorophore absorbs energy it goes 
from the ground singlet electronic state (S0) to a higher energy excited singlet state (S1). A fluorophore 
is usually excited to some higher vibrational level of S1 but it rapidly relax to the lowest vibrational level 
of S1 in a process called internal conversion. Fluorescence emission occurs as the fluorophore decay 
from the singlet electronic excited states to an allowable vibrational level in the electronic ground state108. 
 
Figure 16: The Jablonski diagram of fluorophore excitation, radiative decay and nonradiative decay pathways. E 
represents the energy scale; S0 is the ground singlet electronic state; S1 and S2 are the successively higher energy excited 
singlet electronic states. T1 is the lowest energy triplet state109. 
 
Fluorescence spectroscopy is one of the most useful biophysical techniques available to study 
structure and function of biological molecules, particularly proteins, due to sensitivity, ease of use, and 
flexibility110. It has been used to study protein folding, dynamics, assembly, interactions, as well as 
membrane structure and also has been successfully applied to investigate protein aggregation, including 
amyloid fibril formation58 and the interaction of amyloidogenic proteins with membranes, as well as their 
dynamic structures111.  
Tryptophan, tyrosine and phenylalanine residues are naturally occurring fluorophores in proteins. The 
intrinsic fluorescence of proteins has been extensively explored to study protein dynamics and 
conformational changes110. Extrinsic fluorescent dyes can also be used in various fields of protein 
analysis112. Recently, the use of extrinsic fluorescent dyes such as ANS, Bis-ANS, Nile Red, Thioflavin T 
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and others has increased, because of their versatility, sensitivity and suitability for high-throughput 
screening.  
In this particular work the extrinsic fluorescent dye Thioflavin T is extensively used. 
 
2.2.4.1 – Thio f lav in T 
In 1959, Vassar and Culling were the first to describe the use of Thioflavin T (ThT) (Fig.17) as a 
potent fluorescent marker of amyloid deposits in histology12. They noticed that ThT selectively localized 
amyloid deposits exhibiting a dramatic increase in fluorescent brightness12.  
Further studies expanded the range of applications of ThT from histology to in vitro 
characterization113. This benzathiole dye upon binding to amyloid fibrils displays a dramatic shift of the 
fluorescence excitation maximum (from 385 nm to 450 nm) and the emission maximum (from 445 nm 
to 482 nm) becoming highly fluorescent.  
Despite its common use in the diagnosis of amyloid fibrils in ex vivo, in vitro, and animal model studies 
the molecular mechanism of ThT binding to amyloid fibrils is still being elucidated114.  
In the particular case of the interaction between ThT and TTR amyloid fibrils it has been shown that 
ThT dramatically increases its fluorescence quantum yield when bound to mature amyloid fibrils. 
However, this does not occur in the presence of the native tetramer or the unfolded monomer and only 
a minor increase is observed in the presence of early oligomers and protofibrils115. 
 
 
 
 
 
Figure 17: Thioflavin T structure. 
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2.2.5 - Turbidity assays  
 
The turbidity assays used to probe protein aggregation and for high-throughput screening of in vitro 
amyloid fibrillogenesis inhibitors116 are based on monitoring the absorbance of the sample over time. 
The increase in turbidity is due to protein precipitation under acidic conditions, with fibrils and/or 
amorphous aggregates being formed depending on the pH, temperature and time. These methods are 
sensitive to total insoluble protein since turbidity does not give information on the nature of the 
aggregate species50. 
 
 
2.2.6 – Transmission electron microscopy 
 
Transmission electron microscopy (TEM) is a technique based on the interaction of an electron beam 
with a sample. In a transmission electron microscope a cathode ray source is used to emit and accelerate 
a high-voltage electron beam, which is focused by electrostatic and electromagnetic lenses. When the 
electrons pass through a thin specimen, an image carrying the information about the structure of the 
specimen is formed from the electrons transmitted through the specimen. This image is then magnified 
and focused by an objective lens and appears on an imaging screen that can be a fluorescent screen, 
photographic plate, or light sensitive sensor such as a CCD (charge-coupled device) camera. 
 Because biological macromolecules have low contrast when viewed by TEM, strategies such as 
negative staining are used. In this strategy the stain, typically uranyl acetate, circumscribes the 
macromolecule, the shape of which is deduced from distribution of the stain, which scatters most of the 
electrons.  
TEM offers very powerful magnification and resolution (up to 0.2 nm) and has been used to study 
the morphology of protein aggregates and fibrils117.  
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2.3 – Experimental protocol 
2.3.1 – Sample preparation 
 
After a careful review of the literature several experimental conditions were tested to produce 
amyloid fibrils of WT-TTR. 
 
2.3.1.1 -  WT-TTR f ibr i l s  assembly at  pH 2 with 0.1 M NaCl 
Samples of acid-unfolded TTR at pH 2 were prepared by dialysis against 10 mM HCl for 96 hours at 
4°C in a Slide-A-Lyzer cassette with a molecular weight cut off membrane of 3500 Da. TTR aggregation 
was induced by addition of NaCl to a final concentration of 0.1 M115. Aggregation was carried out for at 
least a week at room temperature. The TTR concentration as tetramer used was approximately 80 µμM.  
TTR   concentration  was   determined   by  UV/visible spectroscopy in a UV500 Spectronic Unicam 
spectrometer by reading the absorption at 280 nm and using the TTR molar absorption coefficient 
(ε280=7,76 x 104 M-1cm-1)55.  
 
2.3.1.2 -  WT-TTR f ibr i l s  assembly at  pH 2 with 0.1 M NaCl fo l lowed by pH 
change to  7.4 
Mature TTR fibrils assembled at pH 2 with 0.1 M NaCl were diluted in phosphate buffered saline 
(PBS) pH 7.4 to the desired final concentration.  
 
2.3.1.3 -  WT-TTR f ibr i l s  assembly  at  pH 4.4 
Aggregation was induced by addition of WT-TTR in 10 mM sodium phosphate, 100 mM KCl and 1 
mM EDTA (pH 7.2) to an equivalent volume of 200 mM sodium acetate, 100 mM KCl and 1 mM 
EDTA (pH 4.32)53.  The resulting solution with a pH of 4.4 was incubated for 72 hours at room 
temperature. The TTR concentration ranged between 7.2 and 40 µM.  
 
2.3.1.4 -  WT-TTR f ibr i l s  assembly at  pH 4.4 fo l lowed by pH change to  7.4 
Mature TTR fibrils assembled at pH 4.4 were diluted five times in Tris-HCl buffer at pH 8.7.  
 32 
2.3.1.4 -  WT-TTR f ibr i l s  induced by heat ing at  pH 7.4 
WT-TTR was dialyzed against 2 mM sodium phosphate and 20 mM NaCl at pH 7.4 over night at 
4°C and diluted in the same buffer to a final concentration as tetramer of 3.6 µM. Fibrillar structures are 
obtained by heating the protein samples at 60°C for 6 days without stirring118. WT-TTR fibrils were then 
maintained at 37°C.  
 
2.3.2 – Dynamic light scattering 
 
To study the effect of doxycycline on WT-TTR fibril disruption, WT-TTR pre-formed fibrils (3.6 
µM) were incubated with or without 50x molar excess of doxycycline and with 0,02% of sodium azide to 
prevent microorganism growth.  
To study the effect of doxycycline on WT-TTR aggregation, doxycycline was added before the 
addition of 200 mM sodium acetate, 100 mM KCl and 1 mM EDTA (WT-TTR fibrils assembled at pH 
4.4) and before the heating of protein samples at 60°C (WT-TTR fibrils induced by heating at pH 7.4). 
TTR, doxycycline and sodium azide concentrations were the same for the fibril disruption tests.   
DLS measurements were carried out in 5 x 5 mm pathlength cuvettes and performed at 25°C or at 
37°C, in the case of WT-TTR fibrils induced by heating at pH 7.4, in a N5 Submicron Particle Size 
Analyzer (Beckman Coulter, Miami, USA) controlled by the PCS software. Each sample was gently 
shaken and measured ten times with an equilibration time of 5 minutes and an acquisition time of 90 
seconds. The sample volume used in these assays was 300 µl.  
All the buffer solutions were previously filtered through 0.2 µm syringe filters (Whatman, England).  
 
2.3.3 – STD NMR 
 
All NMR spectroscopy experiments were performed at 25°C on a Bruker Avance III 400 MHz 
spectrometer equiped with a BBFO probe. 
 NMR samples, with a final volume of 350 µμl, contained 20 µM of WT-TTR fibrils in the 
corresponding buffer, 10% of D2O and a 100x molar excess of doxycycline prepared in dimethyl 
sulfoxide-d6.   
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For STD NMR experiments, a pseudo-2D version of the STD NMR sequence was used for the 
interleaved acquisition of on- and off-resonance spectra. Selective saturation of the protein was achieved 
by a train of Gauss-shaped pulses of 50 ms length each, separated by a 1 ms delay.  
The on-resonance irradiation of the protein was performed at a chemical shift of 0.75 ppm. Off-
resonance irradiation was set at 50 ppm where no protein signals were present. Saturation time was 5 
sec. The total scan number in STD experiments varied between 512 and 1536. Water suppression was 
performed by excitation sculpting. 
 
2.3.4 – Circular dichroism spectroscopy 
 
Far-UV CD data were acquired on an Olis DSM 20 circular dichroism spectropolarimeter 
continuously purged with nitrogen, equipped with a Quantum Northwest CD 150 Temperature-
Controller system and controlled by the Globalworks software. Scans were collected between 195-260 
nm at 1 nm intervals, three spectral scans with an integration time of 5 seconds per nm were averaged. 
The protein concentration used was 3.6 µM, the volume 50 µl and the cuvette pathlength was 0.2 mm. 
Baselines with buffer were also acquired and subtracted from the raw CD data.  
 
2.3.5 – Thioflavin-T assay 
 
ThT was used to probe amyloid formation. A freshly prepared stock solution of ThT (in 5 mM 
glycine–NaOH buffer, pH 9.0) was added to protein solutions (3.6 µM) in the absence or presence of 
50x molar excess of doxycycline relative to protein. The samples final volume was 350 µl and the final 
concentration of ThT was 10 µM. 
The stock solution was previously filtered through 0.2 µm syringe filters and the concentration 
determined by UV/visible spectroscopy in a UV500 Spectronic Unicam spectrometer by reading the 
absorption at 411 nm and using the thioflavin-T molar absorption coefficient (2.2 x 104 M-1cm-1).  
Fluorescence experiments were preformed on a Varian Carey Eclipse spectrofluorometer equiped 
with a temperature controller system and controlled by the Varian Cary Eclipse software version 1.1.  
ThT emission was monitored at 485 nm with the excitation wavelength set to 450 nm. Assays were 
carried out in 5 x 5 mm pathlength cuvettes with excitation and emission slits of 5 nm and continuous 
agitation with a magnetic stirrer. Spectra of ThT fluorescence were collected between 460 and 560 nm 
with an excitation wavelength of 450 nm. Baselines without protein were also acquired and subtracted 
from the corresponding raw data. 
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2.3.6 - Turbidity assays 
 
Absorbance measurements were performed in a 96-well microplate at 450, 500, 550, 600 and 650 nm 
at 25°C or 37°C on a BioTek Eon microplate spectrophotometer controlled by the Gen 5 software 
version 2.01. The plates were shaken in an orbital way during 30 sec before the measurement.  
Sample preparation was performed as described for the DLS assay but in this case the final volume in 
each well was 100 µl. The absorption values of the blanks were determined and subtracted from the 
corresponding raw data.  
 
2.3.7 - Transmission electron microscopy 
 
WT-TTR fibrils were analysed by TEM. The sample aliquots (5 µL) were adsorbed onto carbon 
coated collodium films supported on 400-mesh copper grids for 1 minute. The grids were negatively 
stained with 1% uranyl acetate and visualized using a FEI-Tecnai G2 Spirit Biotwin transmission 
electron microscope equipped with a MegaView III– SIS CCD camera. 
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Chapter 3: Results 
In this work three WT-TTR fibril formation protocols were tested: pH 2 with 0.1 M NaCl, pH 4.4 
and 60°C heating. These protocols and the alteration of sample pH were studied by DLS, turbidimetry, 
CD and TEM. 1H STD NMR was used to study the interaction of doxycycline with WT-TTR fibrils and 
DLS and turbidimetry assays were performed to study the effect of doxycycline on the disruption of 
WT-TTR fibrils. In the DLS assays unimodal size analysis and SDP analysis were performed, despite the 
high polydispersity index of all the samples which was around 1, unimodal size analysis was performed 
to have a quicker and easier assessment of size alteration, however the sizes represented in the graphics 
cannot be considered a good estimation of the real size of fibrils. 
 
3.1 - WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl 
 
 3.1.1 - Study by 1H STD NMR of the interaction of doxycycline with 
WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl  
 
To evaluate if doxycycline was able to bind to WT-TTR fibrils assembled at pH 2 with 0,1 M NaCl, 
1H STD NMR analysis was performed. The 1H–NMR spectrum of the free ligand in the same buffer 
used to prepare WT-TTR fibrils, 1H STD NMR spectrum of doxycycline (2 mM) in the presence of 
TTR fibrils (20 µM) and the off-resonance spectrum are represented in figure 18. The 1H NMR STD 
spectrum of doxycycline in the presence of TTR fibrils (Figure 18B) indicates that doxycycline binds to 
WT-TTR fibrils. The signals present in the STD spectrum identified by their chemical shifts represent 
the doxycycline protons that are in direct contact with the fibrils. Signals from the aromatic protons H8, 
H7 and H9, the protons H5a and H6 and from the three methylic groups are observed. There are 
additional signals between 2,5 and 3 ppm that could not be unambiguously assigned due to the high 
density of resonances in this region. Additionally the resonances of the ligand broaden when in solution 
with the fibrils due to alteration of the relaxation time, which is further evidence of binding.  
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Figure 18: 1H STD NMR of doxycycline (2 mM) in the presence of WT-TTR fibrils (20 µM) assembled at pH 2 and 
0.1 M NaCl. A- Reference 1H NMR spectrum of doxycycline at the corresponding pH; B- 1H STD NMR spectrum with the 
doxycycline protons involved in the binding identified; C-Off resonance spectrum. 
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3.1.2 - Effect of doxycycline on the disruption of WT-TTR fibrils 
assembled at pH 2 with 0.1 M NaCl  
 
The effect of doxycycline on WT-TTR fibrils assembled at pH 2 with 0,1 M NaCl was studied by 
DLS (Figure 19). WT-TTR pre-formed fibrils were incubated either in the absence or presence of a 50x 
molar excess of doxycycline and DLS measurements were carried out everyday until apparent size 
stabilization.  
Right after the addition of doxycycline to the mature pre-formed fibrils (0 days) is observable a 
disruption of the fibrils is observed. The population of particles with a diameter between 100 and 1000 
increases and the population of particles above 5000 nm decreases when compared to the control 
(Figure 19A, 0 days). However this immediate apparent effect was not maintained over time. In the 
following days the mean size increased and the populations of smaller particles decreased (Figure 19A, 7 
days). In spite of this occurrence, when comparing the control with the doxycycline treated fibrils in the 
assay endpoint, 11 days, it is observed an increase in the polydispersity of the samples treated with 
doxycycline, with a larger population of small particles (between 100 and 1000 nm), which indicates fibril 
disruption.   
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Figure 19: DLS analysis of the effect of doxycycline on WT-TTR pre-formed fibrils assembled at pH 2 with 0.1 M 
NaCl. WT-TTR fibrils (3.6 µM) were incubated either in the absence (Control) or presence of a 50x molar excess of 
doxycycline (Doxycycline) for the indicated period of time at room temperature. (A) SDP analysis represented as size 
distribution; (B) Unimodal size analysis. 
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3.2 - WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl that 
undergo pH change to 7.4 
 
3.2.1 - Effect of pH change to 7.4 in WT-TTR fibrils assembled at pH 
2 with 0.1 M NaCl   
 
In the case of WT-TTR the in vitro amyloid fibrillogenesis is often initiated by acidification of the 
medium, the low pH leading to the disassembly of TTR’s quaternary structure followed by partial 
unfolding of the monomer that becomes prone to aggregation119. This process is also affected by other 
factors such as temperature, protein concentration, ionic strength and agitation.  
 Westermark and colleagues proposed the low pH environment, found in lysosomes, as a prerequisite 
for amyloid formation in vivo119,120. This proposal implies the formation of amyloid intermediates 
intracellularly, which is not consistent with the observation that TTR amyloid deposits are extracellular. 
Afterwards Quintas and colleagues demonstrated that the TTR tetramer dissociates to non-native 
monomeric species at pH 7 and nearly physiological ionic strengths, and that the monomeric species 
may self-assemble into high molecular mass aggregates, which contradicted that proposal55.  
The extracellular location of the WT-TTR amyloid deposits is widely demonstrated23. In this location, 
the pH is not acidic but around 7.4. Therefore, to develop a protocol to screen for WT-TTR fibril 
disrupters, mimicking the environment of the fibrils is very important. The pH may affect not only the 
overall structure of the fibrils but also the efficacy of the compound being tested. For this reason the pH 
of WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl was changed to 7.4 diluting the very 
concentrated fibril stock in PBS.  
The effect of pH change was studied by DLS, CD and TEM to observe if this pH alteration induces 
modifications in the size and structure of the WT-TTR fibrils. The DLS results (Figure 20) show that the 
alteration of pH from 2 to 7.4 lead to an immediate increase of particle populations above 10000 nm and 
a decrease in the particle populations between 1000 and 10000 nm (Figure 20B, 0 days) when compared 
to the control sample at pH 2 (Figure 20A, 0 days).  Over time the larger particle populations decreased 
and the particle populations between 100 and 1000 nm increased. Size stabilization started around eight 
days after pH change. In the assay final day, day eleven, the sample at pH 7.4 had larger populations of 
smaller particles (between 100 and 1000 nm) and the populations of particles between 1000 and 10000 
nm remained more similar to the particle populations at pH 2.  
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 The unimodal size analysis is in accordance with the SDP analysis. We can clearly see an increase in 
the size of the fibrils at pH 7.4 in the first three days and a decrease in the overall size over time, in the 
last days of the assay the mean size of the fibrils at pH 7.4 is smaller than at pH 2.  
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Figure 20: DLS analysis of the effect of pH change to 7.4 in WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl. 
(A) SDP analysis represented as size distribution by intensity of WT-TTR fibrils (3.6 µM) assembled at pH 2 with 0.1 M NaCl 
at 0, 8 and 11 days; (B) SDP analysis represented as size distribution of WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl 
that undergo pH change to 7.4 at 0, 8 and 11 days; (C) Unimodal size analysis over time of WT-TTR fibrils assembled at pH 
2 with 0.1 M NaCl and that undergo pH change to 7.4. 
 
The possible changes on the secondary structure of the WT-TTR fibrils were analysed by far-UV CD. 
WT-TTR fibrils have a characteristic far-UV CD spectrum with a minimum around 212 nm.  
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At pH 2 this typical CD spectrum is clearly observed (Figure 21) however at pH 7.4 the minimum at 
212 nm is not as pronounced, indicating a loss in β-sheet secondary structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Far-UV CD spectra of WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl (grey) and of WT-TTR fibrils 
assembled at pH 2 with 0.1 M NaCl that undergo pH change to 7.4 at 24 hours (black). Scans were collected between 
195-260 nm at 1 nm intervals, three spectral scans with an integration time of 5 seconds per nm were averaged. The protein 
concentration used was 3.6 µM and the cuvette pathlength was 0.2 mm. Baselines with buffer were also acquired and 
subtracted from the raw CD data.  
 
The TEM results (Figure 22) corroborated the observations made by DLS. The WT-TTR fibrils, 
which appear as white “lines” in the micrographs, at pH 2 seem to be very long unbranched structures 
(Figure 22A). At pH 7.4 they appear to be a bit shorter and are sometimes bundled together (Figure 
22B).  
As previously stated, the ThT assay is a feasible indication of the presence of amyloid structures. This 
fluorescence assay was also applied to the WT-TTR fibrils at pH 7.4 displaying positive results (Figure 
23). In the fluorescence spectrum the emission maximum around 482 nm results from the binding of 
ThT to amyloid fibrils.  
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Figure 22: : TEM images of WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl (A) and that undergo pH change 
to 7.4 (B). The images were taken approximately one month after pH change using a TTR concentration of 3.6  
µμM. 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Thioflavin-T assay of WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl that undergo pH change to 
7.4. The spectrum of ThT fluorescence was collected between 460 and 560 nm with an excitation wavelength of 450 nm. The 
protein concentration used was 3.6 µM and the cuvette pathlength was 5 mm. A baseline spectrum with buffer and ThT was 
also acquired and subtracted from the raw fluorescence data. 
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3.2.2 - Study by 1H STD NMR of the interaction of doxycycline with 
WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl that undergo pH 
change to 7.4  
 
To access if doxycycline was able to bind to WT-TTR fibrils assembled at pH 2 with 0,1 M NaCl 
after undergoing pH change to 7.4 1H STD NMR was performed. The 1H NMR spectrum of the free 
ligand in the same buffer used to prepare WT-TTR fibrils, the 1H NMR STD spectrum of doxycycline (2 
mM) in the presence of TTR fibrils (20 µM) and the off-resonance spectrum are represented in figure 
24. Similarly to what happens at pH 2 the 1H NMR STD spectrum of doxycycline in the presence of 
TTR fibrils at pH 7.4 (Figure 24B) indicates that doxycycline binds to WT-TTR fibrils. However the 
protons implicated in the binding are not the same. In the STD spectrum only the protons H5a and H6 
and from the three methylic groups are observed. Signals from the aromatic protons were not present. 
There are additional signals between 2,5 and 3 ppm that could not be unambiguously assigned due to the 
high density of resonances in this region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: 1H STD NMR of doxycycline (2 mM) in the presence of WT-TTR fibrils (20 µM) assembled at pH 2 and 
100 mM NaCl that after undergoing pH change to 7.4. A- Reference 1H NMR spectrum of doxycycline at the 
corresponding pH; B- 1H STD NMR spectrum with the doxycycline protons involved in the binding identified; C-Off 
resonance spectrum.  
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3.2.3 - Effect of doxycycline on the disruption of WT-TTR fibrils 
assembled at pH 2 with 0.1 M NaCl that undergo pH change to 7.4  
 
The effect of doxycycline on WT-TTR fibrils assembled at pH 2 with 0,1 M NaCl that undergo pH 
change to 7.4 was studied by DLS (Figure 25). After size stabilization, also followed by DLS (Figure 20), 
WT-TTR fibrils at pH 7.4 were incubated either in the absence or presence of a 50x molar excess of 
doxycycline and DLS measurements were carried out everyday until apparent size stabilization.  
After doxycycline addition there were no immediate relevant effects in the fibril sizes (Figure 25A, 0 
days). These observations were maintained for approximately ten days, after that period of time the 
particle populations with a size over 1000 nm started to decrease in the sample treated with doxycycline 
(Figure 25B, 10 days).  In the assay endpoint, at seventeen days, the sample treated with doxycycline 
didn’t have any significant population of particles equal or bigger to 1000 nm. This was not observed in 
the control sample that had particle populations between 1000 and 10000 nm (Figure 25A, 17 days). 
These observations indicate that doxycycline disrupts WT-TTR fibrils assembled at pH 2 with 0,1 M 
NaCl that undergo pH change to 7.4. The effect is not immediate but it is visible after seventeen days of 
incubation.  
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Figure 25: DLS analysis of the effect of doxycycline on WT-TTR pre-formed fibrils assembled at pH 2 with 0.1 M 
NaCl that undergo pH change to 7.4. WT-TTR fibrils (3.6 µM) were incubated either in the absence (Control) or presence 
of a 50x molar excess of doxycycline (Doxycycline) for the indicated period of time at room temperature. (A) SDP analysis 
represented as size distribution; (B) Unimodal size analysis.  
 
 
A 
B 
Doxycycline 
 
0 days 
 
0 days 
 
17 days 
 
17 days 
 
10 days 
 
10 days 
 
0 5 10 15 20
0
200
400
600
800
1000
Control
Doxycycline4
Time4(days)
Si
ze
4(n
m
)
 46 
3.3 - WT-TTR fibrils assembled at pH 4.4 
 
3.3.1 - Effect of doxycycline on WT-TTR fibril assembly at pH 4.4 
 
To investigate if doxycycline could prevent fibril assembly at pH 4.4 turbidimetry, DLS and 
fluorescence assays were performed. Doxycycline was added to WT-TTR in 10 mM sodium phosphate, 
100 mM KCl and 1 mM EDTA before the addition of an equivalent volume of 200 mM sodium acetate, 
100 mM KCl and 1 mM EDTA. The final concentration of WT-TTR was 3.6 µM and doxycycline 
concentration was 180 µM (50 x molar excess). A control was also performed without the addition of 
doxycycline. Turbidimetry and DLS measurements were performed every day for three days and in the 
sixth day.  
Turbidimetry results (Figure 26) show that doxycycline does not arrest WT-TTR aggregation. In the 
first three days doxycycline seems to promote aggregation but in the sixth day the aggregation is lower in 
the doxycycline treated sample.  
 
 
 
 
 
 
 
 
 
Figure 26: Effect of doxycycline on WT-TTR fibril assembly at pH 4.4 monitored by turbidimetry. Samples were 
incubated either in the absence (control) or presence of a 50 x molar excess of doxycycline for the indicated period of time at 
room temperature. Absorbance measurements were performed in a 96-well microplate at 450, 500, 550, 600 and 650 nm at 
25°C. The percent aggregation was calculated for each wavelength using the following formula: Aggregation (%)= ((Absλ-
Absmin)/(Absmax-Absmin)) x100. The percentages of aggregation for each wavelength were then averaged and represented with 
the corresponding standard deviation. Baselines without protein were also acquired and subtracted from the corresponding 
raw data before the calculation. 
 
The DLS assay also demonstrates that doxycycline doesn’t arrest WT-TTR aggregation at pH 4.4 
(Figure 27). The particle populations distribution of the control and doxycycline treated samples are 
similar in the first three days. Doxycycline marginally increases the size of bigger particle populations in 
the sixth day. Once again unimodal size analysis was performed to have a quicker and easier assessment 
of size alteration despite the high PI of the samples  (Figure 27B). 
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Figure 27: DLS analysis of the effect of doxycycline on WT-TTR fibril assembly at pH 4.4. WT-TTR fibrils (3.6 µM) 
were incubated either in the absence (Control) or presence of a 50x molar excess of doxycycline (Doxycycline) for the 
indicated period of time at room temperature. (A) SDP analysis represented as size distribution; (B) Unimodal size analysis. 
 
The effect of doxycycline on the very first stages of WT-TTR amyloid formation at pH 4.4 was also 
studied. For that purpose a ThT fluorescence assay was performed. Doxycycline was added to WT-TTR 
in 10 mM sodium phosphate, 100 mM KCl and 1 mM EDTA before the addition of an equivalent 
volume of 200 mM sodium acetate, 100 mM KCl and 1 mM EDTA. The final concentration of WT-
TTR was 3.6 µM and doxycycline concentration was 180 µM (50x molar excess). A control was also 
performed without the addition of doxycycline. After that, ThT (10 µM) was added and ThT emission 
was monitored at 485 nm with the excitation wavelength set to 450 nm for twelve hours. This assay 
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demonstrates that doxycycline does not affect the kinetic of WT-TTR amyloid formation at pH 4.4 in 
the first twelve hours of aggregation (Figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: TTR aggregation kinetics monitored by ThT fluorescence. WT-TTR fibrils (3.6 µM) were incubated either 
in the absence (black) or presence of a 50x molar excess of doxycycline (blue) with ThT (10 µM) for twelve hours at 25°C. 
ThT emission was monitored at 485 nm with the excitation wavelength set to 450. Baselines without protein were also 
acquired and subtracted from the corresponding raw data. 
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3.3.2 - Study by 1H STD NMR of the interaction of doxycycline with 
WT-TTR fibrils assembled at pH 4.4  
 
 To access if doxycycline was able to bind to WT-TTR fibrils assembled at pH 4.4 1H STD NMR 
analysis was performed. The 1H NMR spectrum of the free ligand in the same buffer used to prepare 
WT-TTR fibrils, the 1H NMR STD spectrum of doxycycline (2 mM) in the presence of TTR fibrils (20 
µM) and the off-resonance spectrum are represented in figure 29. Doxycycline proton signals are absent 
in the 1H NMR STD spectrum of doxycycline in the presence of TTR fibrils at pH 4.4 (Figure 29B). 
This may be due to the lack of binding or very weak binding between doxycycline and the fibrils, but 
could also be due to a very strong binding, outside the detection limits of the technique or even due to 
other technical reasons such as the physical state of the sample.  Unlike what happens with the other 
fibril samples prepared at pH 2 with 0,1 M NaCl the sample with WT-TTR fibrils assembled at pH 4.4 is 
extremely turbid and the fibrils and aggregates seem to quickly precipitate in the NMR tube.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: 1H STD-NMR of doxycycline (2 mM) in the presence of WT-TTR fibrils (20 µM) assembled at pH 4.4. 
A- Reference 1H NMR spectrum of doxycycline at the corresponding pH; B- 1H STD-NMR spectrum; C- Off resonance 
spectrum. 
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B 
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3.3.3 - Effect of doxycycline on the disruption of WT-TTR fibrils 
assembled at pH 4.4  
 
The effect of doxycycline on WT-TTR fibril disruption was studied by turbidimetry and DLS. In the 
turbidimetry assay doxycycline was added to WT-TTR in 10 mM sodium phosphate, 100 mM KCl and 1 
mM EDTA before the addition of an equivalent volume of 200 mM sodium acetate, 100 mM KCl and 1 
mM EDTA. The final concentration of WT-TTR was 3.6 µM and doxycycline concentration was 180 
µM (50 x molar excess), a control was also performed without the addition of doxycycline. After that 
turbidimetry measurements were performed everyday until apparent stabilization. In this assay fibril 
disruption by doxycycline was observed (Figure 30). A clear decrease in the turbidimetry of doxycycline 
treated samples, observable around the fifteenth day of incubation, implies that the species in solution 
are smaller than in the previous days. This effect increases in the following days reaching a maximum in 
the twenty-first day of doxycycline treatment. 
 
 
 
 
 
 
 
 
Figure 30: Effect of doxycycline on WT-TTR fibril disruption at pH 4.4 monitored by turbidimetry. Samples were 
incubated either in the absence (control) or presence of a 50 x molar excess of doxycycline for the indicated period of time at 
room temperature. Absorbance measurements were performed in a 96-well microplate at 450, 500, 550, 600 and 650 nm at 
25°C. The percent aggregation was calculated for each wavelength using the following formula: Aggregation (%)= ((Absλ-
Absmin)/(Absmax-Absmin)) x100. The percentages of aggregation for each wavelength were then averaged and represented 
with the corresponding standard deviation. Baselines without protein were also acquired and subtracted from the 
corresponding raw data before the calculation. 
 
The conditions described for the turbidimetry assay were repeated in the DLS assay. An additional 
experiment was performed: doxycycline was added to WT-TTR fibrils assembled at pH 4.4 after fibril 
assembly and size stabilization, which occurred at day seven. Similarly to what was verified in the 
turbidimetry assay (Figure 30) the results show that doxycycline disrupts WT-TTR fibrils. This effect is 
not immediate but is noticeable after fifteen days of incubation (Figure 30B), reaching a maximum in the 
twenty-first day. At this point the major particle population in the control sample have sizes ranging 
between 1000 and 10000 nm, in the doxycycline treated sample the most abundant particle populations 
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have a size smaller than 1000 nm. This is not as noticeable in the doxycycline treated sample after fibril 
assembly but nevertheless is noticeable a decrease in the larger size particle populations and an increase 
in the smaller size populations.  
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Figure 31: DLS analysis of the effect of doxycycline on WT-TTR fibrils assembled at pH 4.4. WT-TTR fibrils (3.6 
µM) were incubated in the absence (Control), in the presence of a 50x molar excess of doxycycline (Doxycycline) or 
incubated with a 50x molar excess of doxycycline after fibril assembly (Doxycycline added after fibril assembly) for the 
indicated period of time at room temperature. (A) SDP analysis represented as size distribution; (B) Unimodal size analysis. 
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3.4 - WT-TTR fibrils assembled at pH 4.4 that undergo pH 
change to 7.4 
 
3.4.1 - Effect of pH change to 7.4 in WT-TTR fibrils assembled at pH 
4.4 
 
A 1:5 dilution in Tris-HCl buffer at pH 8.7 of the fibrils assembled at pH 4.4 was performed to 
obtain fibrils at pH 7.4. The effect of pH change was studied by DLS, CD and TEM to observe if this 
alteration induces modifications in the size, structure and morphology of the WT-TTR fibrils. The far-
UV CD spectra (Figure 32) demonstrates that there are no significant alterations in the fibrils secondary 
structure due to the pH change. The DLS results (Figure 33) show that the pH change induces an 
immediate but transitory increase in the size of the fibrils, seen by the increase of populations of bigger 
particle sizes  (Figure 33A, 0 days). In the following days the particle populations of the fibrils that 
undergo pH change became similar to those that constitute the pre-formed fibrils assembled at pH 4.4 
(Figure 33A and B, 3 and 6 days), although with a distribution comprising smaller particles. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Far-UV CD spectra of WT-TTR fibrils assembled at pH 4.4 (grey) and of WT-TTR fibrils assembled at 
pH 4.4 that undergo pH change to 7.4 (black). Scans were collected between 195 and 260 nm at 1 nm intervals. Three 
spectral scans with an integration time of 5 seconds per nm were averaged. The protein concentration used was 3.6 µM and 
the cuvette pathlength was 0.2 mm. Baselines with buffer were also acquired and subtracted from the raw CD data. 
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Figure 33: DLS analysis of the effect of pH change to 7.4 in pre-formed WT-TTR fibrils assembled at pH 4.4. (A) 
SDP analysis represented as size distribution of WT-TTR fibrils (3.6 µM) assembled at pH 4.4 (pH 4.4) (B) SDP analysis 
represented as size distribution of WT-TTR fibrils assembled at pH 4.4 that undergo pH change to 7.4 at 0, 3 and 6 days after 
pH change (pH 7.4) ; (C) Unimodal size analysis over time of WT-TTR fibrils assembled at pH 4.4 that undergo pH change 
to 7.4  
 
 
In the micrographs it is visible that the WT-TTR fibrils assembled at pH 4.4 (Figure 34A) are not 
elongated structures like those assembled at pH 2 with 0.1 M NaCl (Figure 22A). They appear as more 
spheroid/globular structures. The pH change doesn’t seem to alter their morphology (Figure 34B).  
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Figure 34: TEM images of WT-TTR fibrils assembled at pH 4.4 (A) and that undergo pH change to 7.4 (B). 
 
3.4.2 - Effect of doxycycline on WT-TTR fibrils assembled at pH 4.4 
that undergo pH change to 7.4 disruption 
 
The effect of doxycycline on WT-TTR fibrils assembled at pH 4.4 that undergo pH change to 7.4 was 
studied by DLS (Figure 35). After size stabilization, also followed by DLS (Figure 33), WT-TTR fibrils at 
pH 7.4 were incubated either in the absence or presence of a 50x molar excess of doxycycline and DLS 
measurements were carried out everyday until apparent size stabilization. Doxycycline caused an 
immediate and persistent effect on the fibril sizes. The particle populations between 100 and 1000 nm 
increase and the particle populations between 1000 and 10000 decrease with the doxycycline treatment, 
when compared to the control (Figure 35A). This effect reached a maximum at seventeen days where 
almost the particle populations of doxycycline treated samples are comprised between 100 and 1000 nm 
which was not verified in the control samples where the majority of the particle populations are bigger 
than 1000 nm. Therefore it can be concluded that doxycycline disrupts WT-TTR fibrils assembled at pH 
4.4 that undergo pH change to 7.4.  
200 nm 200 nm 
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Figure 35: DLS analysis of the effect of doxycycline on WT-TTR fibril assembled at pH 4.4 that undergo pH 
change to 7.4. WT-TTR fibrils (3.6 µM) were incubated either in the absence (Control) or presence of a 50x molar excess of 
doxycycline (Doxycycline) for the indicated period of time at room temperature. (A) SDP analysis represented as size 
distribution; (B) Unimodal size analysis. 
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3.5 - WT-TTR fibrils induced by heating at pH 7.4 
3.5.1 - WT-TTR fibril assembly induced by heating at pH 7.4 
 
The protocol for WT-TTR fibril assembly induced by heating at pH 7.4 has not been widely used so 
far. Chung and colleagues used CD and calorimetry to demonstrate that heat-induced conformational 
rearrangements enable normal TTR to assemble into pre-fibrils at physiological pH121 and Lundberg and 
colleagues characterised the morphology of heat-induced WT-TTR fibrils by atomic force microscopy118.  
To better characterize the process of fibril assembly turbidimetry, DLS and CD assays were 
performed. Measurements were taken everyday for the first three days, in the sixth day and after two 
days at 37°C (8th day).  
An increase in the turbidimetry can bee seen in the six days of heating (Figure 36), which implies 
aggregation.  The transition from 60°C to 37°C didn’t induce a decrease in turbidimetry indicating that 
the decrease of temperature didn´t cause fibril breakdown (Figure 36, 8th day).  
 
 
 
 
 
 
 
 
Figure 36: WT-TTR fibril assembly induced by heating at pH 7.4 monitored by turbidimetry. Samples were incubated 
at 60°C for the first six days and maintained at 37°C in the last two. Absorbance measurements were performed in a 96-well 
microplate at 450, 500, 550, 600 and 650 nm at 37°C. The percent aggregation was calculated for each wavelength using the 
following formula: Aggregation (%)= ((Absλ-Absmin)/(Absmax-Absmin)) x100. The percentages of aggregation for each 
wavelength were then averaged and represented with the corresponding standard deviation. Baselines without protein were 
also acquired and subtracted from the corresponding raw data before the calculation 
 
The DLS assay confirms these observations. Both SDP and unimodal size analysis indicate fibril 
growth over time (Figure 37). In the SDP analysis an increase in particle populations between 1000 and 
10000 nm and a decrease of particle populations of smaller sizes is visible over time (Figure 37A).  The 
transition from 60°C to 37°C also didn’t induce considerable fibril breakdown because the particle 
populations distribution in the 8th day is similar to that of the 6th day of heating.  
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Figure 37: DLS analysis of WT-TTR fibril assembly induced by heating at pH 7.4. WT-TTR (3.6 µM) was incubated 
at 60°C for the first six days and maintained at 37°C in the last two, measurements were performed at 37°C. (A) SDP analysis 
represented as size distribution by intensity; (B) Unimodal size analysis. 
 
 
The possible changes in secondary structure were analysed by far-UV CD. During the six days of 
incubation of WT-TTR at 60°C and after two days at 37°C there are no considerable alterations in the 
far-UV CD spectra (Figure 38). The characteristic WT-TTR far-UV CD is maintained indicating no 
significant change in the secondary structure due to fibril formation.  
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Figure 38: Far-UV CD spectra of WT-TTR fibril assembly induced by heating at pH 7.4.  WT-TTR (3.6 µM) was 
incubated at 60° C for the first six days and maintained at 37°C in the last two, measurements were performed at 37°C.  Scans 
were collected between 195 and 260 nm at 1 nm intervals. Three spectral scans with an integration time of 5 seconds per nm 
were averaged. The protein concentration used was 3.6 µμM   and   the   cuvette   pathlength  was   0.2  mm.  Baselines with 
buffer were also acquired and subtracted from the raw CD data. 
 
The ThT assay was also applied to the pre-formed WT-TTR fibrils induced by heating at pH 7.4 
displaying positive results (Figure 39). In the fluorescence spectrum the emission maximum is around 
482 nm, which results from the binding of ThT to amyloid fibrils. 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Thioflavin-T assay of pre-formed WT-TTR fibrils induced by heating at pH 7.4. The spectrum of ThT 
fluorescence was collected between 460 and 560 nm with an excitation wavelength of 450 nm. The protein concentration 
used was 3.6 µM and the cuvette pathlength was 5 mm. Baseline with buffer and ThT was also acquired and subtracted from 
the raw fluorescence data. 
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3.5.2 - Study by 1H STD NMR of the interaction of doxycycline with 
WT-TTR fibrils induced by heating at pH 7.4  
 
The interaction between pre-formed WT-TTR fibrils induced by heating at pH 7.4 and 
doxycycline was studied by 1H STD NMR. The 1H NMR STD spectrum of doxycycline (2 mM) in 
the presence of TTR fibrils (20 µM) and the off-resonance spectrum are represented in figure 40. 
The signals present in the 1H STD NMR spectrum (Figure 40A) represent the doxycycline protons 
that are in direct contact with the fibrils and were identified by their chemical shifts. Signals from the 
aromatic protons H8, H7 and H9, the protons H5a and H6 and from the three methylic groups are 
observed. There are additional signals between 2,5 and 3 ppm that could not be unambiguously assigned 
due to the high density of resonances in this region. 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: 1H STD-NMR of doxycycline (2 mM) in the presence of WT-TTR fibrils (20 µM) induced by heating at 
pH 7.4. A- 1H STD-NMR spectrum; B- Off resonance spectrum. 
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3.5.3 – Effect of Doxycycline on WT-TTR fibrils induced by heating 
at pH 7.4 disruption 
 
The effect of doxycycline on pre-formed heat-induced WT-TTR fibrils was studied by DLS. The 
fibrils were incubated either in the absence or presence of a 50x molar excess of doxycycline and DLS 
measurements were carried out everyday until apparent size stabilization. Unimodal size analysis and 
SDP analysis were performed. Doxycycline didn´t have an immediate effect on fibril size, the particle 
populations present in the control sample are similar to the particle populations of the doxycycline 
treated sample (Figure 41A, 0 days).  Over time the particle populations between 100 and 1000 nm 
increased in the doxycycline treated sample, a signal of fibril disruption. At seventeen days of incubation 
it is observed a decrease of particle populations bigger than 1000 nm in size and an increase of particle 
populations between 100 and 1000 nm in the doxycycline treated sample. In the control sample the 
major particle populations remain above 1000 nm (Figure 41A, 17 days). Thus, it can be concluded that 
doxycycline induces fibril disruption of heat-induced WT-TTR fibrils.  
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Figure 41: DLS analysis of the effect of doxycycline on WT-TTR pre-formed fibrils assembled by heating at pH 7.4. 
WT-TTR fibrils (3.6 µM) were incubated either in the absence (Control) or presence of a 50x molar excess of doxycycline 
(Doxycycline) for the indicated period of time at room temperature. (A) SDP analysis represented as size distribution (B) 
Unimodal size analysis.  
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Chapter 4: Discussion  
The choice of an appropriate fibril formation protocol and amyloid fibril model is crucial to the 
identification and characterization of small molecule interactions with WT-TTR amyloid fibrils and 
consequently to the development of a protocol for screening of WT-TTR fibril disrupters.   
Ideally the in vitro formed fibrils would have the same structure and morphology as in vivo fibrils and 
the fibril formation protocol would be as close as possible to the in vivo process of TTR amyloid 
formation, maintaining physiological conditions such as average protein concentration, pH and 
temperature. However the native tetrameric form of WT-TTR has a high conformational stability (∆Gunf 
= 104 kJ/mol, at 37 ºC and pH 7.1)122 and the amyloid formation process in these conditions is a very 
slow process, unsuitable to be used in screening protocols. Acidification is a commonly used method to 
initiate the assembly of TTR amyloid fibrils but the process of fibrillogenesis depends on various 
additional conditions such as temperature, protein concentration, ionic strength, agitation and pH. By 
lowering the pH the tetrameric structure of the protein is disrupted and is dissociated into a monomeric 
structure, different from the monomer at physiological pH. The altered monomers can associate and 
eventually form amyloid fibrils.  
The pH-dependent effects in proteins are mainly electrostatic and originate from changes in the 
protonation states of acidic and basic residues123. Some of the titratable residues in a protein exhibit 
different behaviour compared with that of the isolated residues due to their interactions with other 
residues in the protein and the altered interactions with the solvent124.  Of the 127 aminoacids that 
constitute the WT-TTR monomer 17 are acidic and 16 are basic.  
The first fibril formation protocol used in this work was performed at pH 2 with 0.1 M NaCl. This 
process and his kinetics have already been studied and well characterized58. The acidification at pH 2 
promotes tetramer dissociation and the addition of 0.1 M NaCl induces aggregation because the chloride 
ions shield the positive charges of the protein allowing for a conformational changes and assembly of 
the monomers into oligomers and eventually fibrils. This process is relatively time consuming and 
requires a high concentration of tetrameric WT-TTR to be effective in less time. The fibrils formed at 
this pH have already been studied by TEM and AFM, appearing as thin and long filamentous structures 
that bind ThT118. The TEM results (Figure 22A) confirm these observations concerning fibril 
morphology.   
The pH change to pH 7.4 of pre-formed fibrils at pH 2, performed in this work, was an attempt to 
mimic the in vivo conditions of WT-TTR fibrils. WT-TTR amyloid deposits are extracellular23 and in this 
location the pH is not acidic but around 7.4.  
 64 
Herein the effect of pH modification on mature WT-TTR amyloid fibrils size, structure and 
morphology was studied by DLS, CD and TEM. In a previous study performed by Pires and colleagues 
alterations resulting from transient PBS incubation of WT-TTR protofibril bundles, a structure present 
in the early stages of aggregation induced by acidification, were reported57,125. In this case AFM was used 
to observe that after PBS incubation protofibril bundles disassembled halting the amyloid formation 
process57,125. However the effect of PBS incubation on mature WT-TTR amyloid fibrils assembled at 
pH2 with 0.1 M NaCl had not yet been studied. Our DLS results showed that pH alteration induces 
modifications in the size of the fibrils (Figure 20). After an immediate and transient increase in the size 
of the fibrils (0 days) the particle populations of higher sizes decreased and the particle populations 
between 100 and 1000 nm increased. After eleven days of incubation the most abundant particle 
populations at pH 2 and pH 7.4 are comprised between 1000 and 10000 nm however at pH 7.4 particle 
populations smaller than 1000 (between 100 and 1000 nm) are more frequent.  
The CD results revealed an alteration in the secondary structure of the fibrils due to pH alteration 
(Figure 21). After 24 hours of PBS incubation the CD spectrum indicates a loss of β-sheet secondary 
structure. 
TEM observations reinforce the DLS results. The very long unbranched structures existent at pH 2 
appear to shorten after incubation in PBS for approximately one month (Figure 22B). However the 
overall filamentous morphology is preserved.  At pH 7.4 WT-TTR fibrils remain ThT positive (Figure 
23), a feasible indication of amyloid structures.   
The second fibril formation protocol used was based on WT-TTR acidification at pH 4.4. This 
method is widely used for in vitro WT-TTR amyloid fibrillogenesis inhibitors screening, it is easily 
implemented in medium or high throughput screening formats in tubes or microwell plates50,116. This 
method is less time consuming than the previous method and does not require high concentrations of 
native WT-TTR. Fibrils can be formed at physiological concentrations (3.6 µM).  
Atomic force microscopy studies showed that aggregates formed at the slightly higher pH of 4.0–5.5 
have different morphology, displaying predominantly amorphous structures than the aggregates formed 
at a lower pH118. These aggregates are also different from the in vivo WT-TTR amyloid fibrils. The TEM 
images we obtained also endorse these observations. WT-TTR fibrils assembled at pH 4.4 (Figure 34A) 
are not elongated structures like those assembled at pH 2 with 0.1 M NaCl (Figure 22A) appearing as 
more spheroid/globular structures. Nevertheless these are ThT positive structures118. 
With this protocol turbidity assays are frequently used to monitor the degree of protein aggregation 
and fibril formation. At a pH between 4 and 5 the turbidity is higher, at more acidic pH aggregation does 
not induce a noticeable increase in turbidity118.  
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Once again, to mimic the in vivo conditions of WT-TTR fibrils, the pH was modified to 7.4 by a 1:5 
dilution in Tris-HCl buffer at pH 8.7 of the mature TTR fibrils assembled at pH 4.4. CD, DLS and TEM 
assays (Figure 32, 33 and 34) demonstrated that the pH change does not significantly alter fibril 
structure, size or morphology.   
The third fibril formation protocol is the less well-studied process of the three. Lundberg and 
colleagues characterized temperature-induced fibrils at pH 7.4 by AFM. These fibrils were thicker than 
the in vitro fibrils seen at low pH, appearing to be more similar to fibrils seen in vivo118. Their observations 
could not be confirmed by TEM in this work because a representative micrograph could not be 
obtained.  
To better characterize the aggregation process turbidimetry, DLS and CD assays were performed. 
The increase in turbidimetry verified over the six days of incubation at 60°C incubation (figure 36) and 
the increase in particle populations between 1000 and 10000 nm and decrease of particle populations of 
smaller sizes observed by DLS (Figure 37) imply aggregation. This process was not reverted by 
temperature change to 37°C because turbidimetry and particle populations remained unaltered. The far-
UV CD spectra remained unaltered during the six days of incubation at 60°C and after temperature 
change to 37°C indicating no change in the characteristic β-sheet secondary structure due to fibril 
formation or temperature change (Figure 38). The temperature-induced fibrils are ThT positive (Figure 
39), a feasible indication of amyloid structures.  
Table 3 summarizes the main characteristics and requirements of the three fibril formation protocols. 
The pH 4.4 fibril formation protocol is the less time consuming, has low protein requirements and is 
suitable for pH change to 7.4 but the morphology of the fibrils isn’t similar to the in vivo morphology, 
which is a major drawback. The pH2 with 0.1 M NaCl protocol is the more time consuming and 
requires higher concentrations of protein but it is extremely well characterized. The fibril morphology is 
similar to in vivo but pH change to 7.4 induces alteration on the size and secondary structure of the fibrils 
even thought they remain ThT positive.  The heat-induced fibril formation protocol seems to be a very 
good candidate to be used on WT-TTR fibril disrupters screening. This protocol is not very time 
consuming, has low protein requirements, the fibrils are formed and remain at physiological pH and 
their morphology is similar to the in vivo morphology of WT-TTR fibrils.  
Nevertheless the heat-induced amyloid formation by WT-TTR needs to be better characterized. 
Additional fluorescence studies with ThT or monitoring tryptophan emission over time could help to 
confirm and characterize the aggregation pathway. Further atomic force or transmission electron 
microscopy studies could also be important to characterize the morphology of the aggregates during the 
process. AFM could also characterize the height and periodic substructure of the heat-induced fibrils.   
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Table 3: Characteristics of WT-TTR fibril formation protocols. 
 
In this work the effect of doxycycline on fibril assembly was also studied. The first and third fibril 
formation protocols could not be used. The first would imply a very high doxycycline final 
concentration (around 4 mM) to maintain the 1:50 protein/doxycycline ratio, which is not allowed by its 
relatively low solubility. In the third fibril formation protocol the doxycycline heating at 60°C induced an 
aberrant increase in the supposed size of the fibrils (data not shown) and the solution also became 
brown. The thermostability of doxycycline had already been studied in pharmaceutical formulations 
showing that doxycycline exhibits thermo-degradation after exposure to high temperatures (40-70°C)126 
consequently the assays did not proceed.  
Using the pH 4.4 fibril formation protocol the effect of doxycycline on WT-TTR fibrils assembly was 
studied by turbidimetry, DLS and ThT fluorescence (Figures 26, 27 and 28). Taken together the results 
show that doxycycline does not arrest fibril formation.  
In the development of any screening protocol saving time and resources without compromising the 
selection is crucial. When choosing small molecules that can directly disrupt WT-TTR fibrils the 
interaction of the molecules with the fibrils is essential to the process hence using an assay that can 
probe binding is very important and allow us to make a first selection of the compounds to test.  
1H STD NMR was chosen to probe the interaction between the WT-TTR fibrils and the compound 
being tested, doxycycline, due to its availability, relative ease of application, reduced protein requirements 
and applicability to large molecular weight proteins. However is important to note that this technique 
also has some drawbacks, only being suitable to probe low affinity interactions. 
Doxycycline seems to be relatively stable at pH 2, 4.4 and 7.4. The 1H NMR spectrum of doxycycline 
at pH 7.4, 4.4 and 2 (annex B) doesn’t show alterations on the doxycycline proton signals, which could 
indicate degradation. The 1H NMR spectrum of doxycycline in DMSO can be found in annex A for 
comparison.  
 pH 2 with 0.1 M NaCl pH 4.4 60°C heating 
Protocol duration At least 13 days  3 days 6 days 
Protein requirements High Low Low 
Morphology of the fibrils Long unbranched structures 
 
Spheroid/globular structures  
Amorphous aggregates 
AFM observations 
characterized this 
structures as more similar 
to in vivo WT-TTR 
fibrils118  
Effect of pH change to 
physiological conditions 
Alterations in the size and 
secondary structure of the 
fibrils. 
Fibrils remained ThT 
positive 
 
No effect on size, secondary 
structure or morphology 
 
Not needed, the reaction 
occurs at pH 7.4 
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Different concentrations of WT-TTR were tested in 1H STD NMR preliminary experiments at pH2. 
20 µM was the minimum concentration detectable  and thus was used in the 1H STD NMR assays. 
Examining all the 1H STD NMR spectra is noticiable that doxycycline interacts differently with fibrils 
assembled by the different fibril formation protocols or with fibrils that undergo pH change. The 
doxycycline protons involved in the binding to WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl are 
the aromatic protons and the protons from the three methylic groups (Figure 18). When these fibrils 
undergo pH change to 7.4 the signals from the aromatic protons disappear from the spectrum (Figure 
24) meaning that they are not involved in the interaction. As previously described the pH transition from 
pH 2 to pH 7.4 induces alterations in the structure of the fibrils and can cause changes in the 
protonation states of acidic and basic residues, which may modify the interactions between the fibrils 
and doxycycline. Additionally the protonation state of doxycycline is also changed by the pH transition. 
The pKa values for doxycycline are: pKa1=3.02 ± 0.3, pKa2=7.97 ± 0.15 and pKa3=9.15 ± 0.3
127. 
Therefore at pH 2 all the protonable groups are protonated and at pH 7.4 one of them is not. This may 
also alter the interactions between the fibrils and doxycycline.  
In the 1H NMR STD spectrum of doxycycline in the presence of WT-TTR fibrils assembled at pH 
4.4 doxycycline proton signals are absent (Figure 29B). This result may be due to a very weak or very 
strong binding of doxycycline to the fibrils, to the absence of binding or to other technical aspect. In 
subsequent assays was observed that doxycycline disrupts WT-TTR fibrils assembled at pH 4.4 so the no 
binding hypothesis can be discarded. It is also necessary to take into account that the fibril sample at pH 
4.4 is extremely cloudy and the fibrils seem to precipitate the RMN tube, which may affect the assay 
results.  
The doxycycline protons involved in the binding to heat-induced fibrils (Figure 40) are the same as 
does involved in the binding with WT-TTR fibrils assembled at pH 2 with 0.1 M NaCl. The binding of 
doxycycline to these fibrils is not equal to the binding to WT-TTR fibrils assembled at pH 2 with 0.1 M 
NaCl that undergo pH change to 7.4 despite the pH being the same. The cause of this observation may 
be the different structure of the fibrils. The aminoacids available to interact with the doxycycline may 
not be the same in both causes ergo the binding is different.  
1H STD NMR or other NMR based techniques are not the only techniques that can be used to study 
the binding of small molecules to larger macromolecules. Isothermal titration calorimetry (ITC) is a 
quantitative technique that can determine the binding affinity, enthalpy changes  and binding 
stoichiometry of the interaction between two molecules. This technique is broadly used as a secondary 
screening technique in high throughput screening. It has similar advantages to 1H STD NMR and less 
drawbacks such as the narrow detection limits. ITC provides additional information, namely the 
thermodynamic characterization of the binding, and the determination of the binding affinity is more 
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straigthforward. Therefore, it would be interesting to incorporate ITC in the WT-TTR fibril disrupters 
screening and characterization protocol.  
Herein the disruptive effect of doxycycline on WT-TTR fibrils was evaluated for the first time. In 
previous studies the effect of doxycycline as a fibril disrupter was tested on Leu55Pro or Val30Met 
fibrils94,96. DLS was the technique chosen to study the disruptive effect of doxycycline on the fibrils. This 
technique requires a small quantity of sample and allows a fast analysis being adequate for a screening 
protocol. The instrument used, the N5 Submicron Particle Size Analyser, provides two kinds of analysis: 
the unimodal size analysis and the SDP analysis. The unimodal size analysis that provides the mean size 
of the particles in the sample is not reliable due to the high PI of the fibril samples, but can help to have 
a quicker and easier assessment of size alteration over time. The SDP analysis provides more accurate 
information about the size and distribution of the particles populations in the sample but it is more time 
consuming and harder to perform. This technique was successfully applied in probing the disruptive 
effect of doxycycline on pre-formed WT-TTR fibrils prepared using the different fibril formation 
protocols. The molar excess of doxycycline used in this experiments was 50x, which was the 
concentration used in previous studies with doxycycline and Leu55Pro TTR fibrils94. 
Doxycycline does not have an immediate persistent effect on WT-TTR fibrils. It takes from eleven   
to twenty five days to reach a maximum effect. Doxycycline has a more pronounced disruptive effect on 
fibrils assembled at pH 4.4 and fibrils assembled at pH 4.4 that undergo pH change to 7.4 (Figure 31 and 
35), but the effect is also evident in heat-induced fibrils (Figure 41) and visible in fibrils assembled at pH 
2 with 0.1M NaCl (Figure 19) and fibrils that undergo pH change to 7.4 (Figure 25). As previously 
discussed this diverse effect of doxycycline on the WT-TTR fibrils prepared by the different protocols 
might be attributed to factors such as the pH of the sample or more likely to the different fibril 
structures.  
Turbidimetry was another technique used to probe fibril disruption but it was only successfully 
applied to fibrils assembled at pH 4.4. The results obtained with this technique (Figure 30) were in 
accordance with the DLS results. Fibrils assembled at pH 2 and fibrils assembled at pH 2 that undergo 
pH change to 7.4 don’t have detectable turbidities (data not shown). The heat-induced fibril growth 
could be detected by turbidimetry however when applying this assay in the following of fibril disruption 
the results were inconclusive and didn’t correlate with the DLS assay results (data not shown). At pH 4.4 
the WT-TTR fibrils are not elongated structures like those assembled at pH 2 with 0.1 M NaCl or 
induced by heating, appearing as more spheroid/globular structures classified as amorphous aggregates. 
This different morphology might be the cause of the turbidimetry observed at pH 4.4 and the lack of 
turbidimetry in the other sample conditions.  
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In this study only one concentration of doxycycline was tested, in the future is important to also test 
other concentrations to better characterize the effect of doxycycline. Furthermore the temperature used 
in the doxycycline incubation with the fibrils was room temperature, which is not ideal. It would be 
better to perform these procedures at 37ºC to mimic physiological conditions. This could not be 
accomplished due to technical difficulties. When the samples were incubated at 37ºC in capped quartz 
cuvettes the sample evaporated in a few days and the measurements could not be performed and other 
methods of sample isolation were tested but without success.  
For the development of the fibril disrupters screening protocol would also be important to have 
additional techniques to better characterize the effect of the candidate compounds on the fibrils 
providing more insights about the morphology and specific size of the species resulting from fibril 
disruption. AFM and TEM are suitable candidates for that purpose.  
Given the fact that small oligomeric species are the most cytotoxic species of the aggregation 
pathway, the evaluation of the toxicity of the generated species upon treatment is also very important 
and should be incorporated in the screening protocol. The caspase-3 activation assay on an 
Schawannoma cell line has been used for that purpose128.  
Other aspect concerning toxicity in a screening protocol is the evaluation of the effect of candidate 
compounds on cell viability. A good drug candidate must not compromise cell viability therefore assays 
such as MTT should be incorporated in the screening protocol. Doxycycline is an already approved 
antibiotic and is in clinical trial98 to be approved for the treatment of TTR amyloidosis hence its effect 
on cell viability wasn´t tested in this work.  
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Chapter 5: Conclusion 
The disaggregation of amyloid structures is one of the possible therapeutic strategies for the 
treatment of TTR amyloidosis. To date only a few compounds have been identified as possible fibril 
disruptors. The main goal of this work was to identify and characterize the interaction of small 
molecules with WT-TTR fibrils in order to develop a protocol for WT-TTR fibril disrupters screening. 
The first step to achieve this goal was the selection of an appropriate fibril formation protocol and 
the characterization of the formed fibrils. Assembly at pH 2 with 0.1 M NaCl, assembly at pH 4.4 and 
heat-induced fibril assembly at pH 7.4 were the three methods tested for that purpose. Furthermore the 
possibility to mimic physiological conditions by altering the pH of the fibrils was also studied.   
The heat-induced protocol seems to have some advantages over the other fibril formation protocols 
but requires further characterization. DLS, turbidimetry and CD were the techniques used to follow the 
aggregation process. The formed fibrils also require better characterization and TEM and AFM could be 
used to better describe their morphology and periodic properties. 
Fibrils formed at pH 2 with 0.1 M NaCl that undergo pH change to 7.4 suffer alterations in their size 
and secondary structure but remain ThT positive. These alterations don´t occur with fibrils formed at 
pH 4.4 that undergo the same pH change. The pH 4.4 is not the ideal protocol mainly due to the 
morphology of the fibrils, observed by TEM, being very different from the in vivo morphology of the 
fibrils.  
1H STD NMR was the technique chosen to probe the interaction between the fibrils and the 
compounds being tested, s doxycycline, a known fibril disruptor, was used as reference compound. This 
is an important step in the screening protocol because it allows a first selection of the compounds to be 
tested. Fibril disruption might be a lengthy process and this first selection step based on fibril-compound 
interaction could prevent us to spent time and resources studding an ineffective candidate. 1H STD 
NMR was successfully applied in probing the interaction of doxycycline with WT-TTR fibrils, with the 
results showing that doxycycline interacts diversely with WT-TTR amyloid formed in different sample 
conditions. Alternatively, ITC could be used to probe this interaction. 
Herein the disruptive effect of doxycycline on WT-TTR fibrils was evaluated for the first time. DLS 
was the selected technique to characterize fibril disruption and the results show that doxycycline 
disassembles pre-formed WT-TTR fibrils in all the assembly conditions tested, however this effect is 
more pronounced in WT-TTR fibrils assembled at pH 4.4.  Turbidimetry assays were also used but 
could only be applied to WT-TTR fibrils assembled at pH 4.4, with the results corroborating the DLS 
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assays. In the future, different concentrations of doxycycline should be used to better characterize its 
fibril disassembly effect.  
For further development of the fibril disrupters screening protocol additional techniques to better 
characterize the effect of the candidate compounds on the fibrils should be used. AFM and TEM could 
provide more insights about the morphology and size distribution of the species resulting from fibril 
disruption.  The cytotoxicity of the generated species and the toxicity of the compound should also be 
assessed.  
Globally this work allowed us to choose a good fibril formation protocol candidate, the study of the 
interaction of doxycycline with WT-TTR fibrils and the characterization of its effect on fibril disruption 
and the selection of experimental techniques and conditions to use in the development of the screening 
protocol. Additionally, it was useful in the identification of aspects requiring further investigation. 
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Annexes 
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Figure A: 1H NMR spectrum of doxycycline (6.9 mM) in DMSO. The asterisk corresponds to DMSO-d6.    
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Figure B: 1H NMR spectrum (I) and spectral expansions (II and III) of doxycycline (1 mM) in phosphate saline 
buffered (PBS) pH7.4 (green), acetate buffer pH 4.4 (red) and 10 mM HCl with 0.1 M NaCl pH 2 (blue). The signal 
at 0 ppm corresponds to the TSP reference and the asterisk to DMSO-d6.  
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